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1.1. T cells 
The immune system has evolved as a host defense system against invading 
pathogens. There are many biological structures and different type of cells as a part of this 
system. It is divided into two categories as innate and adaptive immune system. Innate 
immune system provides non-specific recognition of pathogens via detection of pathogen-
associated molecular patterns (PAMPs). It is a fast, first-line response against infections. 
Adaptive immune system, on the other hand, is a more complex, antigen-specific defense 
mechanism. The versatile nature of the adaptive immune system enables the generation 
of effective and highly specific immune components against each infectious agent. In 
addition, it provides long-lasting protection to an infection with the same pathogen by 
forming immunological memory.1 
The T cells are the major players of the adaptive immune system and respond mainly 
to pathogens. They are classified into two main subsets as CD8+ T cells and CD4+ T cells 
based on their distinct functions and co-receptor expression. CD8+ T cells, also known as 
cytotoxic T cells, have the ability to recognize and kill virus-infected cells as well as foreign 
cells. They also might be able to recognize transformed cells such as cancer cells. CD4+ 
T cells are termed helper T cells, they assist the immune response exerted by other 
immune cells like B cells. In this thesis, we will focus primarily on CD8+ T cells, their biology 
and function as potential tools for immunotherapy of leukemias and lymphomas.2 
1.1.1. The T cell receptor 
Each T cell in the body expresses a unique T cell receptor (TCR) which recognizes 
epitopes presented in the context of major histocompatibility complexes (MHCs) on the 
host cell surface. The TCR is a heterodimeric receptor made of two polypeptide pairs either 
as  or  chains. The T cell subset with  TCRs, which makes up a minority of peripheral 
T lymphocytes, link the adaptive and innate immune system and will not be further 
addressed in this study.3 
The  and  chains of a TCR consists of a variable and a constant region. The constant 
region facilitates the heterodimerisation of the two chains and provides the 
transmembrane domain that anchors the TCR to plasma membrane. As the constant 
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region does not have signaling domains, it is noncovalently linked to the CD3 complex and 
a  chain dimer that carry out signal transduction via their immunoreceptor-based tyrosine 
activation motifs (ITAMs).4 The variable region binds to the peptide-MHC (pMHC) 
complexes on target cell surface and thereby confers specificity of the TCR. The  chain 
is encoded by the combination of a variable (V) and a joining (J) gene segment, while the 
 chain contains an additional diversity (D) gene segment. The genes encoding for the 
human TCR and TCR variable chains are found in a germline configuration on 
chromosomes 14 and 7, respectively.5 There are 70 V and at least 61J genes in the TCR 
 locus and 67 V, 2 D and 13 J genes in the TCR  locus.6 The combinatorial diversity of 
TCR variable regions is achieved by combining various segments through a process called 
V(D)J recombination which is carried out by the RAG1 and RAG2 recombinases during T 
cell development in the thymus.7–9 In addition to this, junctional diversity is introduced by 
addition and removal of nucleotides at the junction of different V-J or V-D-J segments. 
These hypervariable loops are called complementary determining region 3 (CDR3) and 
form the center of antigen-binding site of a TCR responsible for recognition of pMHC 
complexes.4,10 
1.1.2. Major histocompatibility complex and antigen presentation 
Major histocompatibility complex (MHC) molecules are cell surface glycoproteins that 
present antigenic peptides derived from proteins to T cells. These heterodimeric molecules 
are divided into two classes as Class I and II molecules depending on the chains they are 
made of, the nature of the peptides they present and the type of T cells they interact with. 
The MHC Class I (MHC-I) molecules are made of a variant  chain and a non-polymorphic 
polypeptide chain -microglobulin (2M).11 They are expressed on the surface of all 
nucleated cells and present peptides derived from all cellular proteins to CD8+ T cells. The 
MHC Class II (MHC-II) molecules are composed of a variant  and a variant  chain.12 
They are expressed explicitly by antigen presenting cells (APCs) such as dendritic cells 
(DCs) and B cells and present peptides to CD4+ T cells. In addition to the peptides derived 
from cellular proteins, the MHC-II can present peptides derived from exogenous antigens 
internalized by endocytosis. 
The MHC locus is organized on chromosome 6 in humans and contain around 200 
genes that are involved in pathways essential for the adaptive immune system. In humans, 
the genes encoding for MHC-I and II belong to the human leukocyte antigen (HLA) 
complex.13 There are three genes coding for Class I  chain named HLA-A, -B and -C and 
three pairs of genes coding for the “classical” Class II  and  chains called HLA-DR, -DP, 
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and -DQ. Other “non-classical” MHC-II molecules are called HLA-DM and HLA-DO. The 
MHC Class I and II genes are co-dominantly expressed and highly polymorphic. Therefore, 
each individual can express up to six different Class I and ten different Class II molecules 
including the non-classical MHC-II. As each MHC allele has different sequence preference 
for peptide binding, co-dominance and polymorphism of MHC molecules provides a 
capacity to present a very broad range of peptides.14 
The MHC-I molecules are made of a variant  chain and a non-polymorphic 
polypeptide chain 2M. The  chain is composed of three main domains namely 1, 2 
and 3. The highly polymorphic 1 and 2 domains form the peptide binding groove of the 
MHC-I, while 3 facilitates heterodimerization via 3-2M interaction, which is essential for 
surface expression and stability of the complex.15 The peptide binding groove of MHC-I 
can only bind to short peptides with an average length of 8-11 amino acids.16 The source 
of the peptides is typically proteasomal degradation products of cellular and nuclear 
proteins including pathogen-derived peptides accumulating intracellularly in case of viral 
infections. Once the degradation takes place, the short peptides are transported by the 
transporter associated with antigen presentation (TAP) complex to the endoplasmic 
reticulum (ER) where MHC-I assembly is carried out by multiple chaperon proteins.17 Next, 
the assembled MHC-I is stabilized by the binding to a peptide. The binding occurs when 
the groove interacts with the peptide via one residue at the carboxyl terminus and one or 
two residues at the amino terminus of the peptide, called the anchor residues.4 Finally, 
peptide-loaded MHC-I complexes are transported to the cell surface through the Golgi 
apparatus.18 The polymorphism of 1 and 2 domains of each MHC allele allows binding 
to different anchor residues increasing the range of peptides displayed on the surface, 
thus enhancing the protein sampling capacity. In addition to that, those sites serve as 
interaction points with TCRs restricting a unique TCR to a single pMHC combination.19 
1.1.3. T cell development and selection in the thymus 
All T cells originate from the hematopoietic stem cells (HSCs) that reside in the bone 
marrow and complete their differentiation and maturation in the thymus. HSCs first 
differentiate into multipotent progenitors (MPPs) that are the common ancestor of all 
myeloid and lymphoid blood cells which then differentiate into common lymphoid 
progenitors (CLPs). Some CLPs can migrate to the thymus, where the interaction with 
thymic stroma initiates a series of proliferation and differentiation events. Initially, T cell 
progenitors do not express a CD3-TCR complex and CD4 or CD8 co-receptors. At this 
stage, they are called double-negative (DN) due to the lack of co-receptor expression. 
Those DN precursors go through a series of phases called DN1 to DN4, then start 
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expressing CD4 and CD8 becoming double positive (DP). Finally, they are positively and 
negatively selected to become fully functional, mature CD4 or CD8 T cells.20 
TCR rearrangement starts at the DN3 phase with the rearrangement of the  chain. 
The upregulation of RAG1 and RAG2 recombinases initiates the V(D)J recombination from 
one of the alleles at the TCR  locus in an attempt to create a functional variable region 
linked to a constant region. The rearranged  chain pairs with an invariant  chain (pre-
T) forming a preliminary form of the TCR called pre-TCR. Production of a functional pre-
TCR prevents the recombination of the other  allele, known as allelic exclusion, whereas 
a thymocyte with a nonfunctional pair can rearrange a new  chain from the other allele. 
The pre-TCR triggers proliferation and cells become double positive (DP) expressing both 
CD4 and CD8 co-receptors. At this DP stage, the thymocytes start rearranging the TCR  
chain. Unlike the  chain, the rearrangement at the TCR  locus does not stop until positive 
selection takes place.21 
In the thymic cortex, DP cells with a rearranged TCR  pair interact with self-antigen-
presenting-MHC-I or MHC-II molecules on the surface of thymic APCs. Only the T cell 
clones that can recognize self-antigen-MHC complexes above a certain affinity threshold 
receive survival signals and are positively selected while the rest dies by “death by 
neglect”.22 The positive selection is essential because this step ensures that all the 
surviving cells bear a TCR capable of interacting with an MHC allele. Additionally, the fate 
of a DP T cell is determined at this step. Cells that interact with an MHC-I molecule lose 
CD4 and remain CD8+ while the ones interacting with and MHC-II molecule lose CD8 and 
become CD4+. A portion of the positively selected cells can bind to self-antigen-MHC 
complexes with a high affinity, which could potentially result in auto-reactivity. These cells 
are removed by a process called negative selection which takes place in thymic medulla. 
T cell clones that recognize self-antigens with a high affinity above a certain threshold 
receive proapoptotic signals and are clonally deleted before they reach maturation, while 
some can differentiate into regulatory T cells.23 Negative selection contributes drastically 
to “central tolerance”, which is a mechanism to prevent autoimmunity by deleting the self-
antigen reactive T cell clones. In summary, the naïve T cells that leave the thymus are 
restricted to a single MHC allele and tolerant to the self-antigens thanks to the 
differentiation and selection processes. 
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1.2. Cancer Immunotherapy 
1.2.1. Immune response to cancer 
The observation that the immune system can recognize entities on tumor cells came 
from a series of tumor transplantation experiments of methylcholanthrene (MCA)-induced 
tumors in inbred mice. Mice immunized with MCA-induced fibrosarcoma were protected 
when challenged with the same tumor but not with a spontaneous tumor. In addition, 
immunization with normal tissue did not protect against MCA-induced tumor transplant 
showing an entity of MCA-induced tumor is responsible for anti-tumor immunity. 24 The 
ability of the immune system to recognize and destroy arising tumor cells by the T cells is 
a concept called immunosurveillance. It was formulated by Burnet in 1970. He 
hypothesized that tumors with neo-antigens can induce immune response resulting in 
tumor regression and control.25 Immunosurveillance is protective against virus-induced 
tumors;26 however, there is controversial views on whether it applies to spontaneous 
tumors.27–29 According to the immunosurveillance theory, a tumor can grow out when a 
tumor cell escapes T cell recognition by losing its immunogenicity. However, in a mouse 
model of sporadic cancer expressing SV40 T oncogenene as tumor antigen, it was shown 
that the tumor evades T cell response not by losing the immunogenicity but inducing 
tolerance.30  
Cancer immunotherapy consists of the use of immune system components such as 
cytokines, therapeutic antibodies and T cells to recognize and eliminate cancer cells. While 
cytokines, such as IL-2, unspecifically induce an upregulation of all T cell responses and 
is antigen-independent, antibodies and T cells are directed towards selected antigens, 
thus possibly being antigen-specific.31 In the following subsections, we will summarize the 
tumor antigens and antigen-specific immunotherapy approaches. 
1.2.2. Tumor antigens 
The tumor antigens fall into two classes as tumor-associated antigens (TAAs) or 
tumor-specific antigens (TSAs). TAAs are non-mutated self-antigens that are 
overexpressed on tumor cells, and are also present on some normal cells to a certain 
extent. They could be tissue differentiation antigens such as CD19 on B cells, MART-1 
and gp100 on melanocytes and Willm’s tumor 1 (WT1) on chronic myelogenous cells in 
some leukemias and HSCs.32 Another class of TAAs are the cancer-testis antigens which 
are expressed normally on germ cells in the testis or ovaries but are reactivated in some 
tumor cells.33 The MAGE family genes and NY-ESO-1 that are expressed on melanomas 
and other cancers fall into this category. The advantage of TAAs is that they are shared 
INTRODUCTION   
 6 
between tumors and individuals increasing the range of patients that could benefit from 
TAA-specific therapies. Yet, targeting TAAs can cause on-target toxicity in normal tissues 
because they are usually shared between tumor and normal cells.33 
TSAs, also termed neoantigens, are derived from somatic mutations in the tumor and 
are truly tumor specific. The point mutations in the protein-coding regions of genes can 
cause amino acid alterations in the protein sequence changing a peptide sequence at the 
anchor residues enabling them to bind to MHC molecules or create a new epitope that can 
be recognized by T cells.34 Mutations in cancer-driver genes are very valuable neoantigens 
to target with TCRs since they are required for the oncogenic transformation and tumors 
cannot evade an immune response by growing variants that lack the corresponding 
mutation. For example, MHC-I-restricted antigenic neoepitopes from such genes like 
KRAS and TP53 have already been described,35,36 although only a minority of the many 
different KRAS and TP53 mutations found in human cancers are truly immunogenic: the 
peptides encompassing the mutation do not fit into the grooves of the most frequent MHC-
I molecules or they only bind with a very weak affinity. Although there are examples of 
shared mutation leading to potentially targetable neoantigens, most of them are patient-
specific. Thus, use of TCRs targeting individual neoantigens is frequently restricted to 
small number of patients and often require development of personalized immunotherapy. 
1.2.3. Antibody-based immunotherapy 
Monoclonal antibodies targeting TAAs on tumor cells have been used in the clinic since 
a long time. They bind to surface antigens and act on tumor cells by directly inducing 
apoptosis, activating the complement system or initiating antibody-dependent cell 
mediated toxicity.31 To date, there is a broad range of solid and hematological cancers that 
can be targeted by antibodies. For instance, an anti-HER2/neu antibody, Trastuzumab, is 
in use for HER2-positive breast cancers. In addition, Rituximab targets the CD20 
molecules on B cells and used against non-Hodgkin B cell lymphomas and B cell 
leukemias. Other examples of antibody targets are CD52, vascular endothelial growth 
factor (VEGF) and epidermal growth factor receptor (EGFR).37 In addition, antibodies can 
be used as targeting agent to deliver anti-cancer agents to the tumor site and in this case, 
they are called antibody-drug conjugates. Bi-specific antibodies make another group of 
antibody-based therapeutics used in cancer therapy. They are artificial antibodies with two 
different antigen specificities that can recognize two different epitopes or antigens allowing 
dual targeting. The bi-specific antibodies can be developed to recognize a TAA and CD3 
molecule on T cells. This serves the purpose of activating and engaging a nonspecific T 
cells to a tumor cell to induce tumor cell lysis.38 In recent years, bio-engineered small 
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antibody fragments are used rather than whole antibody molecules for this purpose. 
Furthermore, the use of immune checkpoint inhibitors can be categorized into this class. 
CTLA4 and PD-1 are expressed on the surface of activated T cells which attenuate T cell 
activity at different stages of T cell response by different means. They keep T cell response 
in a physiological range during response to pathogens and maintain peripheral tolerance 
which protects the host from autoimmunity. Tumors can dysregulate those regulatory 
mechanism to evade the immune response. Use of antibodies against CTLA4 and PD-1 
blocks the inhibitory signals and unleashes the T cell response against tumor.39 While the 
response to immune checkpoint inhibitors depend on the mutational load of the tumor,40,41 
the search for predictive biomarkers is still ongoing as the majority of the patients do not 
respond.42 
1.2.4. Adoptive T cell transfer 
1.2.4.1. Adoptive transfer of non-modified T cells 
The therapeutic effect of graft-versus-leukemia (GvL) reaction observed after an 
allogeneic hematopoietic stem cell transplant (HSCT) could be seen as one of the earliest 
examples of adoptive transfer of non-modified T cells.43,44 The evidence that this 
therapeutic effect is mainly orchestrated by the donor T cells comes from the increased 
rate of relapse in the patients who receive lymphocyte-depleted HSCs.45 This is further 
supported by lower relapse rates associated with donor lymphocyte infusion followed by 
HSCT.46 
Efforts have been implemented on treating tumors using autologous tumor-reactive T 
cells that reside in the tumors and are called tumor infiltrating lymphocytes (TILs). The first 
use of TILs on patients with metastatic melanoma was published by Rosenberg in 1988,47 
which was followed by a trial with a higher number of patients.48 In the second report, they 
showed that transfer of ex vivo expanded autologous TILs in combination with high dose 
IL-2 can induce objective response in 29 of 86 patients.48 The ex vivo expanded cellular 
product is a heterogeneous population of CD4+ and CD8+ T cells with unknown antigen 
specificity and MHC restriction. Strategies were improved identify and expand tumor-
reactive TIL clones to generate more uniform cellular products. The antigenic targets of 
identified TILs include MART-149, gp10050 ad some neoantigens51. The TIL isolation and 
production were extended to other solid tumors such as renal cell carcinoma, breast 
cancer, cervical cancer, neuroblastoma but the highest success rate remains in melanoma 
patients.52  
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1.2.4.2. Adoptive transfer of engineered T cells 
The need to use T cell products with a defined antigen specificity and T cell subtype 
drove the development of techniques aimed to transfer specific antigen receptors to a 
large number of normal T cells to be used in adoptive cell therapy (ACT). These receptors 
can be artificial chimeric antigen receptors (CARs) or natural TCRs. The transfer of the 
transgenes can be done via viral delivery using retroviral or lentiviral vectors or non-viral 
delivery such as “sleeping beauty” transposon/transposase53 and CRISPR/Cas9 
systems54. 
As the name implies, CARs are chimeric antigen receptors with an extracellular single 
chain variable fragment (scFv) antibody domain linked to an intracellular TCR signaling 
domain. The scFv provides antibody-like recognition of the cancer surface antigens, while 
the intracellular domain drives the signaling pathways that lead to T cell activation. CARs 
provide non-MHC-restricted recognition of target cells; therefore, the recognition is 
independent of the MHC alleles of the patients and the antigen processing machinery of 
the tumor cells.55 The antigenic targets of CARs are usually TAAs. The first CAR was 
developed to target CD19 molecule expressed on B cell-derived malignancies and normal 
B cells. It showed great success in the clinic with up to 90% response rates in patients with 
relapsed B cell acute lymphoblastic leukemia revolutionizing cancer immunotherapy.56 
Additional B cell surface markers have been subsequently targeted such as CD20, CD22 
and BCMA.57–59 Further lineage-specific antigens are being evaluated for other kinds of 
tumors. For instance, CD5- and CD7-specific CARs were developed to target T cell 
malignancies.60,61 The examples of targets can be extended to HER2 for some solid 
tumors, carbonic anhydrase IX (CAIX) for renal cell carcinoma, GD2 for neuroblastoma 
and mesothelin and CEA for other solid tumor types.52 
In TCR gene therapy, T cells are equipped with a high-affinity TCR against a TAA or 
TSA that is present in the tumor to be targeted. It represents a refinement and a further 
development of TIL-based immunotherapy. Delivery of a high-affinity TCR to a defined T 
cell population enables generation of cell products with desired antigen specificity and 
MHC restriction. One major drawback of TCR gene therapy is that it can be applied only 
to a fraction of patients that carry both the MHC allele and the tumor antigen. While CAR-
modified T cells are MHC-independent, and therefore can be applied to a broader range 
of patients, they can target only surface antigens on target cells limiting the number of 
targetable TAAs. Unlike CARs, TCRs can recognize epitopes derived from all proteins 
independent of their cellular localization. Therefore, the use TCR-modified T cells can 
expand the repertoire of TAA antigens. For example, intracellular TAAs, such as tissues-
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specific transcription factors can be targets for TCR gene therapy.62 The biggest 
advantage of TCR-modified T cells is that they can recognize tumor specific neoantigens 
allowing development of T cell therapy with minimum or no toxicity. 
1.2.5. Engineered CD8+ T cells in ACT 
The first study showing that TCR gene transfer can redirect human T cells to a tumor 
antigen was published in 1999. A MART-1-specific TCR cloned from the TILs of a 
melanoma patient had cytotoxic effect against HLA-A2+ melanoma cells in vitro.63 
Experiments in mice showed that adoptive transfer of WT-1 specific TCR can eliminate 
leukemia.64 The encouraging results from those studies paved the way to clinical studies 
on ACT of engineered CD8+ T cells. The first clinical trial was done in 2006 by the group 
of Rosenberg on melanoma patients who were refractory to previous IL-2 treatment. They 
engineered the autologous PBLs of the patients with an HLA-A2-restricted MART-1 TCR 
isolated from the TILs of a melanoma patient. The persistence of transduced cells were 
low after 1 month of the infusion and objective clinical response was observed in 13% of 
the patients.65 Although the response rate was lower than the autologous TIL therapy, this 
study has been a pioneering work for new trials targeting several other TAAs. Since then, 
targeting an HLA-A2-restricted epitope of NY-ESO-1 antigen showed some success in 
melanoma, synovial sarcoma and multiple myeloma patients.66–68 A carcinoembryonic 
antigen (CEA)-specific murine TCR was tested on three patients with colorectal cancer, 
however, all patients relapsed after showing 17%-50% reduction in their tumors size and 
developed severe transient inflammatory colitis.69 Nine patients with melanoma and 
synovial sarcoma were treated with T cells transduced to express affinity-enhanced 
MAGE-A3-specific TCR isolated from HLA-A2-transgenic mouse. Regression was 
achieved in 5/9 patients, however, 3 developed serious neurological toxicity.70 They could 
not pinpoint the antigenic source of off-target recognition but proposed the TCR 
recognized another member of the MAGE family, MAGE-A12, which is expressed on some 
neuronal cells. Another MAGE-A3 TCR restricted to HLA-A1 allele was linked to 
cardiovascular toxicity and eventual death of the two patients involved.71 This was due to 
unexpected cross-reactivity of the TCR against titin, a large protein expressed in the heart. 
These extreme cases demonstrated the power of TCR gene therapy, while drawing the 
attention to the importance of selecting safe TAAs and careful testing normal tissues for 
potential toxicity by the TCR.  
1.2.6. ABabDII mice 
In theory, there are no high-affinity TCRs in the repertoire of an individual against TAAs 
because of the negative selection events and central tolerance. However, cell populations 
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with high-affinity TCRs against certain melanocyte differentiation antigens such as MART-
1 and cancer testis antigens such as MAGE-A1 have been found among TILs and 
circulating lymphocytes of melanoma patients.49,72 There are two major reasons why such 
high-affinity TCRs against self-epitopes exist. First, in rare events, high-affinity TCRs 
targeting self-antigens can escape negative selection. Second, the epitope (as in the case 
of MART-1) or the antigen (e.g. MAGE-A1) is not expressed in the thymus, hence, 
negative selection does not apply.73,74 Yet, such antigens are rare and in order to broaden 
the repertoire of antigen and MHC restriction that is targetable in a variety of cancer types, 
it is possible to generate TCRs with desired specificity and avidity by avoiding negative 
selection.  
Several approaches have been developed to circumvent the tolerance. First, T cells 
from an individual negative for a particular HLA-allele, who does not have tolerance 
against peptides presented by that HLA allele, can be primed in vitro with peptide-loaded 
T2 cells75 or autologous DCs electroporated with the HLA allele that present the epitopes 
of a given TAA.76 So, as an example, TCRs against a HLA-A2-restricted peptide of a given 
antigen can be selected from an HLA-A2 negative donor whose T cells never met before 
the peptide in the context of HLA-A2. This leads to the generation of a TCR of allogeneic 
nature. Because the T cells do not undergo negative selection for that HLA allele, the 
TCRs bear the risk of recognizing the MHC-I molecules of the host independent of the 
peptide presented on it. Selection of truly peptide-specific TCRs is therefore difficult and 
must be screened against a possibly largest number of HLA-alleles and peptides to 
exclude reactivity. A second approach is the use of HLA transgenic mice, which lack 
tolerance to many human self-antigens. However, this method comes with its limitations. 
In this mouse, the murine TCRs are selected on human MHC, hence, they often have low 
avidity. They require affinity maturation by in vitro mutagenesis to reach high-avidity for 
successful tumor rejection in the clinic.77 Another drawback is that the rearranged TCRs 
are of mouse origin and the variable regions might induce immune reaction in humans 
limiting their applicability.78 To overcome the limitations of both of those approaches, 
ABabDII mice were raised in the lab: another mouse model, which is transgenic for both 
the human HLA-A2 molecule and the entire TCR  and  gene loci. These mice can be 
immunized with HLA-A2 restricted human epitopes to raise high affinity class I TCRs.79 
The use of ABabDII mice provides solutions to the drawbacks of the first two approaches. 
The risk of HLA directed allogeneic toxicity is lower because the ABabDII-derived TCRs 
are negatively selected on human HLA-A2. Next, unlike the mouse-derived TCRs, the 
rearranged novel TCRs from ABabDII mice should not induce immune response because 
it uses human TCR genes. Furthermore, the ABabDII mice select human TCRs on human 
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MHC enhancing the isolation of TCRs with high-affinity against TAAs.80 Taken together 
ABabDII mouse present itself as a valuable tool for identification of therapeutic TCRs 
against tumor antigens. 
1.3. Acute Myeloid Leukemia (AML) 
Acute myeloid leukemia (AML) is a hematological malignancy characterized by 
uncontrolled growth and differentiation of myeloid cells. The leukemic cells originate from 
immature cells of the bone marrow, which are mostly myeloid progenitor cells incapable 
of further differentiation, and in rare cases, truly stem cells capable of both myeloid and 
lymphoid differentiation (mixed lineage leukemias, MLL). Immature cells accumulate in the 
bone marrow, and depending on the presence of adhesion molecules or chemokine 
receptors, they may invade the peripheral blood and sometimes even organs, particularly 
skin and mucosa, liver, spleen, lymph nodes, bone, and central nervous system.81  
AML can occur at any age, but is increasingly frequent in the older population median 
age of diagnosis of 70 years.82 The general incidence is around 4 cases in 100.000 people, 
but with an occurrence of around 100 cases among 100.000 individuals aged over 70 
years.83 Current treatments cure 35-40% of the patients younger than 60 years of age (will 
be referred as younger patients) and 5-15% of the patients older than 60 years of age (will 
be referred as older patients).84 The mortality rate of patients older than 65 years old still 
remains 70% within 1 year of diagnosis.85 
The disease prognostic factors can be divided into two groups as patient-associated 
factors and disease-related factors. Patient-associated factors such as age and co-
morbidity are important for prediction of treatment-associated early death, while disease-
related factors such as white blood cell count and particularly the genetic landscape of the 
leukemic cells predict the response to treatment.86 The combination of both factors is 
essential for deciding a particular therapeutic approach such as standard or intensive 
therapy (including aggressive approaches such as allogeneic stem cell transplantation) as 
well as the integration of novel therapeutics that are increasingly being developed as 
selective targets of particular genetic alterations in cellular pathways that govern growth 
and differentiation of hematopoietic cells.86 
Until recently, AML was classified in 8 different subtypes, M0-M7, on the basis of the 
differentiation pattern of the cells.87 According to a new classification announced in 2016 
by the World Health Organization (WHO), AML is divided into 7 different types based on 
morphology, immunophenotype and clinical parameters combined with genetic factors. 
Those types are (i) AML with recurrent genetic abnormalities (including 11 subtypes), (ii) 
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AML with myelodysplasia-related changes, (iii) Therapy-related myeloid neoplasms, (iv) 
AML not otherwise specified (including subtypes analog to the FAB-subtypes), (v) Myeloid 
sarcoma, (vi) Myeloid proliferations related to Down syndrome and (vii) Leukemias of 
ambiguous lineage. An eighth entity consists of (viii) neoplastic proliferation of 
plasmacytoid dendritic cells.88 With improved use of cytogenetic testing, leukemia 
classification is becoming more complicated, with the occurrence of particular genetic 
alteration determining the response of the disease to therapy and therefore the prognosis 
of the disease. More than a hundred different recurrent genetic alterations have been 
defined. Currently, some genetic alterations with prognostic relevance are found with 
higher frequency in AML patients and therefore have clinical relevance. WHO defined 11 
subgroups of AML based on the chromosomal translocations and recurrent mutations with 
prognostic relevance.88,89 The subgroups of AML defined by recurrent genetic alterations 
is continuously increasing and there is a realistic hope that with improved and deeper 
genetic analysis of AML, the pathogenesis and ultimately the therapy of the disease will 
be better understood leading to better, individualized treatment options. Additionally, 
European LeukemiaNet (ELN), a European network with the goal of  leukemia research, 
diagnosis, and treatment, categorised AML as favorable, intermediate and adverse based 
on the cytogenetic profile of the neoplastic cells for better diagnosis and management in 
the clinic.90  
1.3.1. Standard treatment 
The main objective of AML therapy is to induce remission and prevent disease relapse. 
The treatment consists of two phases: induction therapy, which has the goal of eliminating 
as many leukemic cells as possible, and consolidation therapy, which has the goal of 
destroying any potentially residual leukemic cell which may have survived the induction 
phase, and of preventing disease recurrence.86 
The intensity of induction therapy depends on patient-associated prognostic factors. 
Most of the younger patients and older patients that are considered to be “biologically fit” 
receive intensive induction therapy consisting of a combination of the chemotherapeutic 
agent cytarabine (Ara-C), most frequently at a very high dosage, combined with an 
anthracycline drug such as daunorubicin or idarubicin. This combination is usually referred 
to as 7+3 scheme (7 days of cytarabine, 3 days of anthracycline).91 Two to three weeks 
after chemotherapy, a bone marrow evaluation is performed. Complete remission (CR) is 
assumed when the number of immature cells (which possibly include residual leukemic 
cells) is below 5%.90 If CR is not achieved, a further round of induction therapy, sometimes 
at a higher dosage or including additional drugs, is administered. If then the disease 
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persists (more than 5% leukemic cells in the bone marrow), the leukemia is considered to 
be refractory to the therapy and the prognosis is usually grim. 
Patients in CR receive consolidation or post-remission therapy, which may differ 
according to age, morbidity, complications arise during induction therapy, and the quality 
of response. Post-remission therapy may include one or more cycles of chemotherapy, 
frequently including higher dosage cytarabine (HDAC), or allogeneic stem cell 
transplantation.92 The latter is used usually in younger patients considered to have a very 
high risk of relapse (see next chapter) or in patients who experienced a relapse and after 
a novel chemotherapy round could achieve a “second remission”. 
1.3.2. Hematopoietic stem cell transplantation (HSCT) 
The biggest challenge in the management of AML is the high relapse rate which occurs 
in 10-40% of the patient population.93 Allogeneic-HSCT from an HLA-matched donor is the 
most efficient treatment method for high-risk or relapsed AML to date.94 The HSC donor is 
usually an HLA-identical sibling donor, and sometimes an HLA-matched unrelated donor 
who might belong to the extended family of the patient or selected from a worldwide bone 
marrow databank. The donor is selected on the basis of HLA matching between the donor 
and the patient. Different centers have different matching criteria. The donor can be a 
10/10 match meaning HLA-A, -B, -C, -DRB1 and DQB1 alleles are identical with the 
patient, and an 8/8 match when HLA-A, -B, -C and -DRB1 compatibility is sought.95  
The high cure rate of HCST; which is around 15-20% in AML and can be as high as 
80% in chronic myeloid leukemia (CML),96 depends on two factors. First, the patient 
receives higher-dose chemotherapy than induction therapy that has high toxicity both 
against the leukemic cells and the HSCs of the patient.97 Survival after high-dose 
chemotherapy is possible only because the bone marrow function is completely 
reconstituted by the HSCs of the donor, which is administered 24 hours after the wash-out 
of the chemotherapy from the body. Second, the donor lymphocytes in the transferred 
HSCs, although usually matched for most of the HLA-alleles, can still recognize 
hematopoietic cell-specific antigens of the host that differ slightly in their amino acid 
sequence from the donor mainly due to single nucleotide polymorphisms (SNPs) in the 
coding regions of the genes (so-called minor histocompatibility antigens).98 Immunological 
recognition of such antigens leads to the elimination of the leukemic cells bearing them. 
This effect that is usually referred to as the Graft-versus-Leukemia (GvL) effect, and in 
reality, in most cases, it is an “anti-recipient-hematopoiesis” effect.96 As a drawback, 
however, immune recognition can also be directed against normal cells of the patient in 
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other tissues such as skin, liver, gut, and lungs causing severe, sometimes lethal Graft-
versus-Host Disease (GvHD). Despite many efforts for years, it is impossible so far to 
clearly separate the GvL from the GvHD by manipulating either the transplant, the 
“conditioning regimen” used to enable engraftment of the donor stem cells, or the patient 
by administering medications after infusion of the donor cells. Initial evidence on GvL in 
humans came in 1979 with the observation that patients who do not develop GvHD had 
2.5 times higher relapse rate.44. There is now high level of agreement that the most 
significant contribution of allogeneic-HSCT to cure is mediated by this immune recognition.  
1.3.3. Small molecules and antibody-based therapeutics 
The standard “7+3” regimen has been the backbone of AML treatment for the past 40 
years now. Only in the last few years a number of novel drugs have entered the arena of 
AML therapy, mostly as a result of better understanding of the molecular pathways 
involved in leukemogenesis and of extensive molecular genetic characterization of AML 
patients in large study cohorts.99 Those novel therapeutics can broadly be categorized as 
tyrosine kinase inhibitors, cell cycle and signaling inhibitors, epigenetic modulators, new 
cytotoxic agents, nuclear export inhibitors and antibody-based therapeutics targeting AML-
specific antigens.86 Research on tyrosine kinase inhibitors that target wild type and 
mutated forms of FLT3, which is involved in differentiation and are have received the most 
attention due to prognostic value of FLT3 in AML.100 Other tyrosine kinase inhibitors have 
been used in clinical studies, but have not been approved for treatment, a number of other 
small molecule inhibitors are being developed and will enter therapy in the next 
year(s).Another popular class of drugs is epigenetic modulators that particularly target 
mutated isocitrate dehydrogenase (IDH)1 and IDH2 in AML. Although these drugs 
represent a welcome addition to the spectrum of AML therapeutics, so far, it appears that 
these drugs alone will not be able to cure the large majority of patients, indicating the need 
for further improvement. Considering that the majority of the patient population is aged, 
immunotherapy might represent a most desirable approach for AML. 
Antibody therapy for AML includes the use of monoclonal antibodies targeting AML-
specific antigens as well as antibody-drug conjugates. Gentuzumab Ozogmicin, an an 
tibody-drug conjugate targeting CD33 to deliver aDNA-damaging agent to AML cells, is 
the first of its class to be approved by FDA in 2000.101 Several antibodies targeting other 
AML antigens such as CD123, CLL-1 and FLT3 have been developed. Additionally, there 
are bi-specific antibodies that target CD3 molecules on T cells and CD33,CD123 or CLL-
1 on AMLs with the aim to engage unspecific T cells to AML cells.102 
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1.3.4. Adoptive T cell therapy for AML 
The limited efficacy and high toxicity of current treatments drove the urgent need 
to develop more effective therapeutics for refractory AML. The growing attention on ACT 
after the success of CD19-CAR in B-cell malignancies has led to the development of AML-
specific CARs and TCRs. AML-specific antibody targets were chosen as TAAs to develop 
CAR-T cells. CD123 was the first antigen that was targeted with a CD123-CAR T cells. 
Despite CD123-CAR induced rejection of primary AML in vivo, there was significant toxicity 
to hematopoiesis in a xenograft model, so this approach never made it to clinical 
application.103 Later, a CD33-CAR was also shown to reject primary AML in xenografts, 
yet caused anticipated hematopoietic toxicity.104 Most of the AML-specific surface antigens 
are present on myeloid cells and HSCs, hence causing the CAR-related toxicity. Toxicity 
was addressed by generating a CD33-CAR resistant hematopoietic system by autologous 
transfer of CD33 knock-out HSCs followed by CAR-T cell infusion.105 
Similar efforts were put on the generation of AML-specific TCRs, which extended 
the range of the targetable antigens from surface molecules to cellular proteins. For 
instance, WT1, a transcription factor predominantly overexpressed in AML, is the most 
attractive AML-specific target for TCR gene therapy. A T cell clone recognizing an HLA-
A24*02 restricted epitope of WT1 was identified from the peripheral blood of one out of 
three HLA-A24*02 positive healthy individuals.106 The T cell clone efficiently lysed 
leukemic cells isolated from AML and ALL patients, and did not show any toxicity to HLA-
A24*02 positive HSCs in vitro. In a Phase I trial, eight patients received T cells transduced 
with the TCR of the mentioned T cell clone. Although no toxicity was observed in the 
patients, the success rate was low. Only two patients had decrease of blasts in bone 
marrow, one had stable disease, while five of them had progressive disease.107 
Furthermore, an HLA-A2 restricted epitope (WT1126) was targeted by multiple groups with 
the aim to generate WT1 specific T cell response. A T cell clone of allogeneic origin against 
WT1126 was described by Gao and his colleagues. This clone was shown to be effective 
against WT1+ cell lines and safe against healthy CD34+ in vitro.108 Same epitope was used 
to develop a peptide-based vaccine which was tested on eight patients with myeloid 
malignancies. A single dose was shown to induce a short-lived CD8+ T cell response 
detected by tetramer staining of the peripheral blood cells. Although the cytotoxicity 
assessment of the tetramer-positive CD8+ T cells was not performed, this approach was 
claimed to be safe and effective based on reduction of WT1 mRNA detected from the 
patient blood.109 The most recent study on 12 AML patients showed that a WT-1 TCR 
isolated from the periphery of an healthy HLA-A2+ individual targeting the WT1126 can 
prevent relapse in all patients involved without causing any GvDH or toxicity.110 
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Additionally, other TCRs targeting AML-specific TAAs have been identified and evaluated 
such as HLA-A2 and HLA-A*24:02-restricted TERT-specific TCRs111 and HLA-B7 
restricted MPO-1-specific TCR112. 
1.3.5. FLT3 as an AML-specific antigen 
Fsm-like tyrosine kinase 3 (FLT3) is a tyrosine kinase receptor that is expressed by 
HSCs and is crucial for normal hematopoiesis. Activation of FLT3 by binding to FLT3L 
triggers the phosphatidylinositol 3-kinase (PI3K) and RAS signal transduction pathways 
which regulate the proliferation and differentiation of HSCs.113 It is expressed at very high 
levels in 70-90% of the AML patients and enhances proliferation and survival of leukemic 
cells. Additionally, several different mutations of FLT3 have been identified to contribute 
to the pathogenesis of the disease. For instance, FLT3 internal tandem duplication (FLT3-
ITD) has been linked to poor prognosis of AML.114 FLT3 has been an attractive therapeutic 
target due to its significant role on leukemic cell survival and abundant expression in AML. 
A lot of work has been put on developing FLT3-specific tyrosine kinase inhibitors with 
reduced toxicity.115  
We selected FLT3 as a target antigen because it is overexpressed in (i) AML and (ii) 
HSCs in the bone marrow. In our envisaged approach, HLA-A2 restricted FLT3-specific T 
cells expanded from an HLA-A2- donor would eradicate the circulating and marrow 
resident FLT3+ AML cells as well as the hematopoietic stem cells of an HLA-A2+ patient. 
The bone marrow should be reconstituted with stem cells derived from the same HLA-A2- 
donor: This approach could be done in the context of a haploidentical transplantation from 
a family related donor where at least 50% of the HLA-alleles are matched, or in the context 
of a so-called 9/10, single HLA-mismatch transplantation, whereby the only different HLA 
allele between host and donor would be HLA-A2. Lacking the appropriate peptide-
embedding MHC moiety, the newly introduced bone marrow would not be recognized by 
the FLT3-specific TCRs: indeed, the elimination of the host residual hematopoiesis along 
with the host-hematopoiesis-derived leukemic cells should be facilitated, allowing for a 
more efficient engraftment as compared to the standard approach, where transplant 
rejection and loss of chimerism is associated with leukemia relapse in some patients.116 
Adoptively transferred TCR-transduced T cells would be expected to form memory T cells 
in the patient and provide long term persistence in the periphery, thus prevent any potential 
relapse by keeping the proliferation of the patient’s bone marrow cells under control. The 
therapeutic TCRs would need to have a high-affinity for the target antigen for efficient 
tumor eradication. In order to circumvent the tolerance that is present against FLT3 as a 
self-antigen, and based on the advantages of ABabDII mice mentioned in section 1.2.6, 
  INTRODUCTION 
 17 
we decided to employ this model for identification and selection of high-affinity TCRs 
against FLT3.  
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2. Aim of the thesis 
Based on the information given in the previous chapter, in this thesis we aim answering 
the questions below. 
• Can we induce T cell response in ABabDII mouse against HLA-A2 
restricted epitopes of human FLT3? 
• Are the in silico predicted epitopes naturally processed and presented? 
• Do the identified epitopes serve as clinically relevant tumor-rejection 
epitopes? 
• Is FLT3 a safe target for TCR gene therapy for AML in the context of the 
planned approach? 
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3. Materials and Methods 
3.1. Cell lines 
The human AML cell line THP1 (FLT3+/HLA-A2+) was purchased from ATCC. The 
human B cell precursor leukemia cell line SEM and the human AML cell line MV;4-11 (both 
FLT3+/HLA-A2-) were purchased from Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures. THP1 cells was cultivated in RPMI 1640 medium 
supplemented with 10% FCS and 50 µM β-mercaptoethanol. The human CML cell lines 
K562 and MV-4;11 were maintained in RPMI medium supplemented with 10% FBS. The 
SEM cell line was kept in IMDM medium supplemented with 10% FBS. TAP-deficient EBV-
transformed B cell line T2 were maintained in RPMI medium supplemented with 10% FBS. 
K562, SEM and MV-4;11 cell lines expressing HLA-A2 were generated by -retroviral 
transduction with pMP71 vector carrying HLA-A2 molecule which was a gift from Uckert 
Lab, MDC. K562 cells with FLT3 and THP1 cells overexpressing FLT3 were generated by 
transducing the pMP71 vector carrying wild type FLT3. FLT3 and HLA-A2 surface 
expression of cell lines were assessed by FACS staining with antibodies against human 
FLT3-Alexa Fluor 647 (BD Biosciences, San Jose, CA, USA) and human HLA-A2-PE 
(Clone BB7.2, BD Biosciences, San Jose, CA, USA). FACS analysis was done with BD 
FACS Canto II (BD Biosciences, San Jose, CA, USA) and data were analyzed with FlowJo 
version 10.0.8 (Tree Star, Inc., Ashland, OR, USA).  
3.2. Selection of epitopes 
The full length human FLT3 protein sequence was obtained from NCBI database 
(Reference number: NP_004110.2). The sequence was submitted to NetMHC V3.4 for 
prediction of binding to HLA-A2 allele. Epitope length was defined as 9-mers. Two of the 
predicted epitopes with binding affinities higher than 60 nM and different than the mouse 
FLT3 were selected for immunization. 
3.3. Immunization of ABabDII mice 
Predicted peptides were dissolved in DMSO solvent as indicated by the supplier to a 
concentration of 2 mg/ml. Mice were immunized on day 0 and boosted on day 21 with 150 
µg of peptide in a 1:1 solution of incomplete Freund’s adjuvant (IFA) and 50 µg CpG1826 
by subcutaneous injection. Blood was collected 7 days after each boost and blood cells 
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were cultured with 10-6 M peptide overnight. To analyze peripheral response, cells were 
first treated with Fc block (BD Biosciences, San Jose, CA, USA), stained with antibody 
against mouse CD8-PerCP (BD Biosciences, San Jose, CA, USA), then fixed and stained 
with antibody against mouse IFN--APC (BD Biosciences, San Jose, CA, USA). Animals 
were boosted in 21-day intervals until peripheral response was observed. 
Mice with IFN-secreting CD8+ T cells in the periphery were sacrificed. Spleen and 
inguinal lymph nodes of reactive mice were collected. CD4+ T cells were depleted by CD4 
microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). 1x106 splenocytes were 
seeded per well of a 24-well plate and expanded for 10 days in RPMI 1640 medium 
supplemented with 10% FBS gold, HEPES, NEAA, Sodium Pyruvate, 50 µM β-
mercaptoethanol, 20 IU/ml human IL-2 and 10-8 M peptide. Splenocytes were stimulated 
with 10-6 M peptide for 4 h before mouse IFN secretion assay (Miltenyi Biotech, Bergisch 
Gladbach, Germany). The cells were treated with Fc Block, stained with antibodies against 
mouse CD3-APC and mouse CD8-PerCP (BD Biosciences, San Jose, CA, USA). IFN- 
secreting CD8+ T cells were sorted with BD FACS Aria III (BD Biosciences, San Jose, CA, 
USA) to RTL lysis buffer for RNA isolation with RNeasy Micro Kit (Qiagen, Hilden, 
Germany).  
3.4. Identification and cloning of TCRs 
5’RACE-ready cDNA was synthesized with SMARTer RACE kit (Clontech, CA, USA) 
according to instructions of the manufacturer. cDNA was diluted 1:3 prior to use. TCRA 
and TCRB variable chains were amplified by 5’RACE-PCR in a 50 μL reaction mix of 5 μL 
diluted cDNA, 2X Q5 Hot Start High-Fidelity master mix (New England Biosciences, 
Ipswich, MA, USA), 5 μL forward primer from the SMARTer RACE kit (10X Universal 
Primer A Mix (UPM)) and 0.5 μM reverse primers for TCRA: 5’-
CGGCCACTTTCAGGAGGAGGATTCGGACC-3’ or TCRB:5’- 
CCGTAGAACTGGACTTGACAGCGGAAGTGG-3’. Initial denaturation was done at 98°C 
for 2 min seconds followed by 30 cycles of denaturation at 98°C for 30 s, annealing at 72°c 
for 30 s and elongation at 72°C for 45 s. Annealing temperature was decreased by 2°C at 
every 5 cycles for the first 10 cycles. Reaction was carried out for total 35 cycles. Final 
elongation was done at 72°C for 5 min. 
PCR products were separated on a 2% agarose gel. Bands corresponding to the 
correct size were eluted from the gel and cloned using Zero Blunt TOPO PCR Cloning Kit 
(Invitrogen) and sequenced with SP6 primer. Dominant TCR-α/β chains were selected and 
paired. The TCR constant regions were replaced with mouse counterparts. Paired TCR-
  MATERIALS AND METHODS 
 21 
α/β chains were linked with a p2A element. TCR cassette was codon optimized, 
synthesized by GeneArt (Thermo Fisher Scientific, Waltham, MA, USA) and cloned into 
pMP71 by restriction site cloning using the NotI and EcoRI cut sites. 
3.5. Virus production 
HEKT-GALV-g/p cells were transfected with 18 µg pMP71 vector carrying the TCR 
cassette. The virus supernatant was collected 48 h and 72 h after transfection. 1x106 
human PBMCs were stimulated on anti-CD3/anti-CD28 coated plates in RPMI 1640 
medium supplemented with 10% FBS, HEPES, 100 IU/ml IL-2 and transduced with virus 
supernatant at 48 h and 72 h after stimulation. Transduction efficiency was determined by 
FACS staining for human CD8-APC (BD Biosciences, San Jose, CA, USA) and mouse 
TRBC-PE (Biolegend, San Diego, CA, USA). TCR-transduced-hPBMCs were expanded 
in T cell medium supplemented with 100 IU/ml IL-2 for 10 days and kept in 10 IU/ml IL-2 
supplemented medium for 2 days before the co-culture. 
3.6. Functional assays 
T2 cells were loaded with serial dilutions of peptides at 10-5 M to 10-12 M for peptide 
titration experiments. Target cells were selected based on their HLA-A2 and FLT3 
expression and labeled with 1 µM CFSE (ab113853, Abcam, Cambridge, UK) prior to 
seeding. 2x104 target cells and 2x104 TCR-transduced cells were seeded in 200uL final 
volume in a 96-well format to reach 1:1 effector to target ratio. Cell-free supernatant was 
collected after overnight incubation to detect IFN- secretion by ELISA. Cells were 
collected for further analysis and stained with antibodies against human CD137-PE (BD 
Biosciences, San Jose, CA, USA), human CD8-APC-H7 (BD Biosciences, San Jose, CA, 
USA), mouse TRBC-APC (Biolegend, San Diego, CA, USA) and run on BD FACSCanto 
II Flow cytometer. Data was analyzed with FlowJo version 10.0.8. 
3.7. FLT3 cloning 
Total RNA was isolated from THP1 cell line with RNeasy mini RNA isolation kit 
(Qiagen, Hilden, Germany). cDNA was synthesized from 500 ng total RNA with 
Superscript II (Invitrogen) using random hexamer primers according to manufacturer’s 
instructions. Full length FLT3 was amplified with the primers F:5’-
TATGGCGGCCGCGCCACCATGCCGGCGTT-3’ and R:5’- 
CAGGCTCAGGTCGAAGATTCGTAA-3’. Empty MP71 vector backbone with Not1 sticky 
end at 5’ end and blunt end at 3’ was generated by digesting with EcoRI (Thermo Fisher 
Scientific, Waltham, MA, USA), filling in the vector with Klenow fragment (Thermo Fisher 
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Scientific, Waltham, MA, USA) to generate a blunt end followed by NotI (Thermo Fisher 
Scientific, Waltham, MA, USA) digestion and subseguent gel isolation. PCR product was 
cloned into pMP71 by restriction site cloning using Not1 sticky end on 5’ end and blunt 3’ 
end. 
3.8. FLT3 expression profiling 
TissueScan™ human normal cDNA array and human brain cDNA array were 
purchased from OriGene. Primers were designed to detect 236 bp amplicon of FLT3 
transcript as F: 5’- CTGAATTGCCAGCCACATTTTG- 3’ and R: 5’-
GGAACGCTCTCAGATATGCAG- 3’. PCR was performed in a total reaction volume of 25 
µL using 2X Q5 Polymerase Master Mix (New England Biosciences, Ipswich, MA, USA) 
with 0.5 µM of each primer. Initial denaturation was done at 98°C for 30 s followed by 35 
cycles of denaturation at 98°C for 10 s, annealing at 66°C for 30 s and elongation at 72°C 
for 30 s. Final elongation was done at 72°C for 2 min. GAPDH was amplified with primers 
F: 5’- AGAAGGCTGGGGCTCATTTG-3’ and R: 5’- AGGGGCCATCCACAGTCTTC-3’ as 
internal control. PCR products were visualized on 2% agarose gel. 
Snap-frozen healthy brain sections from autopsy samples were provided by the 
Department of Neuropathology (Charité Universitätsmedizin Berlin, Germany) in 
accordance with ethical statement. Cryo-sectioned tissue weighing between 30 mg and 
40 mg was used for RNA isolation. Total RNA was isolated using the RNeasy Lipid Tissue 
mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. cDNA 
was synthesized from 500 ng total RNA with Superscript IV (Invitrogen) using random 
hexamer primers. FLT3 and GAPDH amplicons were amplified with the primers listed and 
cycle conditions stated above. 
3.9. Western blot analysis 
Total protein was extracted from 100 mg to 120 mg pieces of brain sections and FLT3 
positive cell lines using N-PER neuronal protein extraction reagent (Thermo Fisher 
Scientific, Waltham, MA, USA) according to manufacturer’s instructions. Total protein was 
quantified with BCA assay. 100 µg total protein from brain sections and 40 µg total protein 
from control cell lines were mixed with 4X Laemmli sample buffer (Biorad, Hercules, CA, 
USA) in 30 µL final volume, cooked 95°C for 5 min. The samples were resolved by SDS 
polyacrylamide gel electrophoresis (PAGE) using pre-casted polyacrylamide gels (Mini-
PROTEAN TGX Precast Gel, 4-20%, Biorad, Hercules, CA, USA), transferred to 
nitrocellulose membrane, probed with a polyclonal rabbit anti-human FLT3 antibody (1:500 
dilution, clone 8F2, Cell Signaling Technology, Danvers, MA, USA) and then with HPR-
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conjugated goat anti-rabbit IgG (1:2000 dilution, Cell Signaling Technology, Danvers, MA, 
USA). Bands were visualized by chemiluminescence (ECL-Plus; Amersham Pharmacia 
Biotech, Little Chalfont, UK) detection using Chemidoc MP Imaging System (Biorad, 
Hercules, CA, USA). Images were analyzed with Image Lab software (Biorad, Hercules, 
CA, USA). Membrane was stripped for re-probing with monoclonal mouse anti-human β-
actin antibody (1:10000 dilution, Sigma-Aldrich, St. Louis, MO,USA) followed by HRP-
conjugated anti-mouse IgG (1:25000 dilution, Sigma-Aldrich, St. Louis, MO,USA) for 
loading control. 
3.10. Immunohistochemical and immunofluorescence 
procedures 
Immunofluorescence and immunohistochemical staining was performed on formalin-
fixed, paraffin-embedded (FFPE) tissue sections (4 μm-thick) according to standard 
procedures. The following primary and secondary antibodies were used: polyclonal rabbit 
anti-FLT3 (1:50, LS-A7148, Lifespan Biosciences inc., Seattle, WA, USA), monoclonal 
rabbit anti-Calbindin (1:100, clone C26D12, Cell Signaling, Frankfurt, Germany), 
monoclonal mouse anti-CD56 (1:100, clone ERIC-1, Bio-Rad, Puchheim, Germany), 
Alexa Fluor® 488-conjugated goat anti-mouse IgG (1:500, Dianova, Hamburg, Germany), 
Cy3-conjugated goat anti-rabbit IgG (1:500, Dianova, Hamburg, Germany). The 
immunofluorescence counterstaining was performed with VECTASHIELD® Mounting 
Medium containing 4’,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
Burlingame, CA). Immunohistochemical staining of FFPE tissue sections (4 μm-thick) was 
performed on a VENTANA Benchmark XT automated staining instrument according to the 
manufacturer’s instructions. Slides were de-paraffinized using EZ prep solution (Ventana 
Medical Systems, Tucson, AZ) for 30 minutes at 75 °C. Antigen retrieval was 
accomplished on the automated stainer using CC1 solution (Ventana Medical Systems, 
Tucson, AZ) for 60 minutes at 95 °C. Briefly, primary antibodies were applied and 
developed using the iVIEW DAB Detection Kit (Ventana Medical Systems) and the 
ultraView Universal Alkaline Phosphatase Red Detection Kit (Ventana Medical Systems). 
All slides were counterstained with hematoxylin for 4 minutes. Omission of primary 
antibodies as control for nonspecific binding of the secondary antibody resulted in absence 
of any labeling. To validate our immunohistochemical and immunofluorescence staining 
we used different positive control tissues fixed and processed in similar manner to the test 
sections and known to contain the target molecule, e.g. tonsil tissue. 
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3.11. Confocal laser scanning microscopy 
For confocal microscopy, a Leica TCS SP5 confocal laser scanning microscope 
controlled by LAS AF scan software (Leica Microsystem, Wetzlar, Germany) was used. 
Images were taken simultaneously and assembled to stacks.  
 




4.1. Identification of FLT3-specific TCRs in ABabDII mice 
To generate T cell responses against FLT3839 and FLT3986 peptides, we immunized 
ABabDII mice with either of the epitopes as summarized in Table 1. FLT3839 had two and 
FLT398 had three amino acid differences compared to the mouse homolog (Figure 1a). 
Mice 6782 and 6547 had IFN- secreting CD8+ T cells in the periphery after the 2nd boost 
while mice 6780 and 6456 did not show any response after the 10 th boost (Figure 1b). 
Mice were sacrificed either after peripheral response was detected or due to old age. 
FLT3839- or FLT3986- reactive CD8+ T cells were expanded in vitro for 10 days, labeled with 
IFN- capture assay and isolated by FACS for subsequent identification of predominant 
TCR  and  chain rearrangements (Figure 1c). 
 
Table 1 Detailed immunisation schedule of mice. Two mice were immunized for each of the two 
epitopes. The binding affinities were predicted by NetMHC V3.4. The numbers used to tag the mice were later 













FLT3839 IMSDSNYVV 6 
6546 10 700 
6547 2 213 
FLT3986 GLLSPQAQV 56 
6780 10 2500 
6782 2 65300 
 




Figure 1 Identification of FLT3-specific TCRs from ABabDII mice a) Homology of human and mouse FLT3 
spanning the in silico predicted epitopes b) Blood were collected from mice 7 days after each injection and 
were cultured in the presence of 1 M peptide overnight as specific stimulus to detect peripheral CD8+ T cell 
response. IFN-+-CD8+ T cells were detected in the periphery by performing intracellular IFN- staining and 
analyzed by FACS.  Blood cells were stimulated with anti-CD3 and anti-CD28 antibodies as positive control. 
Cells cultured with an irrelevant peptide and without any peptide served as negative control. A representative 
analysis was shown from the mouse 6782. c) Spleen and inguinal lymph nodes were collected from the mice 
and cultured in vitro for 10 days to expand peptide reactive CD8+ T cells. IFN-+/CD8+ population in the gate 
was sorted by IFN- capture assay for RNA isolation. A representative set of plots was shown in the figure. 
Sequencing of 5’-RACE products revealed dominant TCR  and  variable chain 
rearrangements from mice 6780, 6782 and 6546 (Table 2). We did not observe any 
preferred TRV or TRV gene usage for the FLT3986 epitope. We could identify the TRV 
chain from mouse 6547 but not the TRV since the 5’-RACE PCR did not work for this 
chain (data not shown). A TCR cassette was constructed as described in the methods 
section and cloned into the pMP71 vector for retroviral transduction of human PBLs.  
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Table 2 TCR  and  variable chain rearrangements identified from ABabDII mice immunized with either 
FLT3839 (IMS) or FLT3986 (GLL) epitopes. 
TCR Frequency TCRα/β V/D/J genes CDR3 
6780-GLL 
55% TRAV12-1*01 TRAJ26*01  CVVNMDYGQNFVF 
60% TRBV5-6*01 TRBJ2-1*01 TRBD2*01 CASSLEAGYNEQFF 
6782-GLL 
91% TRAV12-2*02 TRAJ26*01  CAVDNYGQNFVF 
94% TRBV12-3*01 TRBJ2-3*01 TRBD2*02 CASSFGRLDTQYF 
6546-IMS 
89% TRAV12-2*02 TRAJ40*01  CAVNRGSGTYKYIF 
60% TRBV2*01 TRBJ2-7*01 TRBD1*01 CASSPGTTYEQYF 
6547-IMS 
TRVA chain could not be identified 
100% TRBV6-2*01 TRBJ2-1*01 TRBD2*01 CASSYIAGINEQFF 
 
4.2. Re-expression of TCRs in human PBLs 
In order to verify that the identified TCR  and  pairings are correct and recognize the 
respective epitopes presented on HLA-A2, human PBLs were transduced with a -
retroviral vector, pMP71, carrying the TCRs with murinized constant regions to avoid 
mispairing with the endogenous TCRs. Transduced cells were stained against the mouse 
TCR constant  chain and human CD8 to confirm re-expression of the TCRs. Transduction 
rate varied between 20-50% depending on the virus titer of different production batches 
(Figure 2, upper panel). Furthermore, cells were stained with FLT3839-HLA-A2 (IMS) or 
FLT3986-HLA-A2 (GLL) tetramers to confirm TCR-pMHC binding. Staining with the 
tetramer showed tetramer-positive populations demonstrating that TCR  and   pairings 
were correct. When gated on TCR-positive cells for analysis, we saw that 6780-GLL and 
6546-IMS TCRs required presence of CD8 molecule to bind to the tetramer. However, not 
all 6780-GLL and 6546-IMS TCR transduced CD8+ T cells bound to the tetramer (Figure 
2, lower panel). In case of 6782-GLL TCR, the T cells did not require the CD8 molecule 
for tetramer binding. The majority of the CD8- T cell fraction was bound by tetramer forming 
31.5% of the whole population. In addition, almost all of CD8+ T cells expressing the 6782-
GLL TCR were bound to the tetramer (62.8% of the whole population).  
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Figure 2 Re-expression of TCRs on human PBLs. Human PBLs were transduced with -retroviral vectors 
carrying the TCRs. Transduction efficiency was assessed by FACS analysis for mouse TCR  constant chain 
(mTRBC) and CD8 expression (upper panel). Transduced cells were further analyzed for tetramer binding 
(lower panel). For this analysis, cells were gated on mTRBC to exclude non-transduced cells in the population 
and visualized for tetramer staining and CD8 expression. All TCRs bound to their respective tetramers. A TCR 
recognizing a tyrosinase-derived epitope served as the control TCR. Plots are representative of multiple 
experiments where wimilar results were obtained from different PBL donors. 
4.3. Evaluation of functionality of identified TCRs 
 Next, to assess the affinity and specificity of the identified TCRs, transduced T cells 
were co-cultured with T2 cells pulsed with FLT3839 or FLT3986 peptides from 10-5 M to 10-12 
M concentration. IFN- release showed that all TCRs recognize their cognate peptide 
when loaded on HLA-A2 (Figure 3a). Among all TCRs, 6780-GLL showed the highest 
degree of IFN- release. This TCR reached half-maximum IFN- release at 17.91 nM 
peptide concentration corresponding to the lowest EC50 value and the highest affinity to 
the pMHC complex. 6782-GLL had almost one-log lower affinity compared to 6780-GLL 
with the highest EC50 value of 100 nM. 6546-IMS had the lowest absolute IFN- release 
but an intermediate EC50 with 33.6 nM (Figure 3b). We concluded that all TCRs recognize 
their respective pMHC complexes when presented on the cell surface but to different 
extents. 




Figure 3 Peptide titration on T2 cells TCR-transduced effector T cells were co-cultured overnight with 
peptide pulsed T2 cells at an effector to target ratio of 1:1. a) IFN- secretion was detected from the cell-free 
supernatant by ELISA. All three TCRs recognized the peptide when present on T2 cells. One representative 
example of peptide titration out of three donors is shown. b) The peptide concentration required to achieve 
half-maximum IFN- release (EC50) was calculated by non-linear regression to estimate affinity of TCRs.  
 
Many studies describing the generation of therapeutic TCRs rely on in silico prediction 
of epitope processing and presentation. NetMHC, a neural network-based tool trained on 
big datasets of HLA-A2 bound peptides has very high accuracy in predicting potential 
epitopes derived from certain antigens. However, binding prediction does not necessarily 
mean that a given peptide is presented on the MHC complex: so, we did not have yet 
experimental evidence that FLT3839 and FLT3986 peptides are naturally processed by the 
proteasome and loaded on the HLA-A2 molecule. In order to investigate that, we 
generated a K562 cell line expressing FLT3 and HLA-A2, as a single MHC class I allele, 
to be used as target cells in recognition and killing experiments (Figure 4a). 6780-GLL 
TCR recognized K562 cells expressing both HLA-A2 and FLT3 proving that the FLT3986 
epitope is naturally processed and presented. K562 cells with HLA-A2 only but lacking 
FLT3 were not recognized indicating that 6780-GLL mediated target recognition is pMHC 
specific. We could not detect any IFN- release from 6782-GLL and 6546-IMS transduced 
effector cells (Figure 4b). Knowing that FLT3986 is processed and presented, we can 
suggest 6782-GLL TCR has too low affinity to recognize pMHC level generated by 
proteasome. Lack of recognition by 6546-IMS, on the other hand, does not provide enough 
proof on natural procession and presentation of FLT3839 epitope. It could be simply because 
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Figure 4 Co-culture with the K562 cells a) K562 cells were retrovirally transduced to stably express HLA-
A2 molecule alone or in combination with FLT3 as shown by FACS staining. b) 6780-GLL and 6782-GLL TCR 
transduced cells released IFN- to peptide-pulsed K562 cells expressing HLA-A2 molecule. No IFN- was 
detected from 6546-IMS transduced cells even in the presence of the peptide. Only 6780-GLL transduced 
cells recognized K562 cells co-expressing HLA-A2 and FLT3. 
 
As the next step, we sought out to determine whether FLT3-specific TCRs recognize 
other cell lines that naturally express FLT3. This is important because cells that are 
genetically modified to express a given protein frequently produce much larger amounts 
of the protein and therefore generate more epitopes derived from that protein as compared 
to physiological cells. THP1 cells naturally express FLT3 and HLA-A2. Additionally, we 
generated FLT3-overexpressing THP1 cells by retroviral transduction (Figure 5a). SEM 
and MV-4;11 cells express FLT3 endogenously and were transduced stably to express 
HLA-A2 molecule as shown by FACS analysis (Figure 5a). We could not detect any IFN-
 release by effector cells against any of the target cells mentioned above. Neither over-
expression of FLT3 on THP1 nor IFN- pre-treatment of THP1 cells to increase MHC-I 
expression elicited any IFN- release (data not shown). 
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To address whether target cells induce T cell activation at all, we analyzed effector 
cells for CD137 upregulation after overnight co-culture. We were able to detect CD137 
upregulation in very low percentage of 6780-GLL T cells after co-culture with THP1 cells, 
but this might be considered as background activation. Ectopic expression of FLT3 in 
THP1 cells induced enhanced CD137 upregulation on 6780-GLL cells (Figure 5b). Peptide 
pulsed THP1 cells activated 35% of TCR-transduced 6780-GLL and 6782-GLL cells 
showing the TCR-modified T cells are capable of activation. In parallel, we detected 




Figure 5 Co-culture with cell lines expressing FLT3 a) FLT3 expression level on the surface of the cell lines 
was assesed by FACS analysis. THP1 cell line was transduced with FLT3 to generate an FLT3-overexpressing 
clone. The cell lines that did not express HLA-A2 were transduced to stably express it and single cell clones 
with desired expression level were selected. b) TCR-transduced T cells were co-cultured overnight with THP1 
cells and CD137 upregulation on effector cells was analyzed by FACS as an indicator of effector cell activation. 
THP1 cells alone did not induce considerable level of CD137 upregulation of effector cells. Overexpression of 
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FLT3 on THP1 cells induced activation of 6780-GLL transduced T cells. THP1 cells pulsed with FLT3986 
peptide prior to the co-culture also induced effector cell activation c) Only 6780-GLL TCR transduced effector 
cells upregulated CD137 after overnight co-culture with SEM and MV-4;11 expressing HLA-A2. 
4.4. FLT3 expression profiling 
4.4.1. Detection of FLT3 transcript from cDNA tissue arrays 
In parallel to the experiments needed to demonstrate TCR specificity and efficacy, we 
conducted a number of studies in order to evaluate the assumption from the literature that 
FLT3 is specifically expressed only in hematopoietic cells. This is crucial in order to avoid 
potential on-target/off-tumor toxicity of a given TCR in case of clinical application. In order 
to check FLT3 expression in different healthy human tissues by RT-PCR, we first wanted 
to evaluate the detection limit of our PCR reaction. For this, we did serial dilution of the 
FLT3+ cell line THP1 from 106 cells down to 10 cells in PBS and mixed each dilution with 
106 cells of the FLT3- cell line K652. After 35 cycles of PCR, we could detect the 236 bp 
amplicon corresponding to FLT3 from as low as 10 cells. As expected, we did not detect 
any FLT3 transcript from K562 cells only. We could detect GAPDH indicating the cDNAs 
were intact (Figure 6). 
 
 
Figure 6 Optimization of FLT3 PCR THP1 (FLT3+) cells were titrated from 106 to 10 cells and mixed with 106 
K562 (FLT3-) cells. FLT3 was amplified to estimate the lowest number of FLT3+ cells that can be detected in 
a given RNA isolate.   
After showing that our PCR had high sensitivity in detecting FLT3 transcripts, we 
sought to determine FLT3 expression in normal human tissues. For this purpose, we did 
RT-PCR to commercially available cDNA array representing 48 major healthy human 
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tissues including bone marrow, lymph node, peripheral blood lymphocytes, spleen and 
thymus. In addition, we detected the amplicon corresponding to the FLT3 transcript from 
other tissues such as lung and pancreas. The presence of FLT3 in those tissues can be 
explained by the tissue resident activated dendritic cells in the islet Langerhans of 




Figure 7 Investigation of FLT3 expression in human tissues FLT3 expression was analyzed by PCR using 
cDNA array representing 48 different healthy tissues of the human body. We detected 256 bp amplicon 
corresponding to the FLT3 transcript from the tissues of hematopoietic origin such as bone marrow, spleen 
and lymph nodes. Unexpectedly, the PCR product was detected in other tissues such as brain and pancreas 
revealing those tissues for potential on-target toxicity.  
 
To investigate which brain section expresses FLT3, we did another RT-PCR with the 
cDNA array representing 24 different anatomical brain regions. We detected the amplicon 
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detected in cerebellum (Figure 8a). PCR products were sequenced to confirm amplified 
sequence corresponds to FLT3 amplicon (Figure 8b). 
 
 
Figure 8 Detection of FLT3 from human neural tissues a) The expression of FLT3 was investigated in 
detail from a cDNA array representing 24 distinct anatomical sections of central nervous system by PCR. The 
high expression of FLT3 was detected in cerebellar sections. Lower expression was observed in S.nigra, pons 
and spinal cord. b) The detected PCR products were sanger sequenced and aligned to the wild type human 
FLT3 sequence revealing the amplified region is not an unspecific product but maps to FLT3.  
4.4.2. Detection of FLT3 in iPSC-derived human cardiomyocytes 
It was reported by Pfister et al. that mouse cardiomyocytes express very high level of 
FLT3 on the surface.117 Unlike them, we detected only a very faint band from the cDNA 
from left ventricule of human heart (Figure 7). In order to verify our results, we obtained 
induced pluripotent stem cell (iPSC)-derived human cardiomyocytes from the Berlin 
Institute of Health (BIH) Stem cells core facility. The cardiomyocytes were thawed and 
RNA was collected on day 2 and day 7 after thawing. In addition, the cells were harvested 
on the same days for FACS analysis of both intracellular and surface FLT3 expression. 
The cells were stained at the same intensity with the anti-FLT3 antibody and isotype 
control antibody meaning the FLT3 protein could not be detected from iPSC-derived 






































































































































































































































----GACAGAAACC  CAAGCTGGAG  AATACCTACT  TTTTATTCAG  AGTGAAGCTA  CCAATTACAC  AATATTGTTT  ACAGTGAGTA  TAAGAAATAC  CCTGCTTTAC  ACATTAAGA A  GACCTTACTT----
----GACAGAAACC  CAAGCTGGAG  AATACCTACT  TTTTATTCAG  AGTGAAGCTA  CCAATTACAC  AATATTGTTT  ACAGTGAGTA  TAAGAAATAC  CCTGCTTTAC  ACATTAAGAA  GACCTTACTT----
----GACAGAAACC  CAAGCTGGAG  AATACCTACT  TTTTATTCAG  AGTGAAGCTA  CCAATTACAC  AATATTGTTT  ACAGTGAGTA  TAAGAAATAC  CCTGCTTTAC  ACATTAAGAA  GACCTTACTT----
----GACAGAAACC  CAAGCTGGAG  AATACCTACT  TTTTATTCAG  AGTGAAGCTA  CCAATTACAC  AATATTGTTT  ACAGTGAGTA  TAAGAAATAC  CCTGCTTTAC  ACATTAAGAA  GACCTTACTT----
----GACAGAAACC  CAAGCTGGAG  AATACCTACT  TTTTATTCAG  AGTGAAGCTA  CCAATTACAC  AATATTGTTT  ACAGTGAGTA  TAAGAAATAC  CCTGCTTTAC  ACATTAAGAA  GACCTTACTT----
----GACAGAAACC  CAAGCTGGAG  AATACCTACT  TTTTATTCAG  AGTGAAGCTA  CCAATTACAC  AATATTGTTT  ACAGTGAGTA  TAAGAANAAC  CCTGNTTNAC  ANATNAAGAN  NACCTTANTT----
----GACAGAAACC  CAAGCTGGAG  AATACCTACT  TTTTATTCAG  AGTGAAGCTA  CCAATTACAC  AATATTGTTT  ACAGTGAGTA  TAAGAAATAC  CCTGCTTTAC  ACATTAAGAA  GACCTTACTT----











Spinal cord  
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intensity (MFI) either on the surface and in the cytoplasm of the cells when stained with 
the anti-FLT3 antibody or isotype control (Figure 9a). 
In addition to the attempts to detect the FLT3 protein on iPSC-derived cardiomyocytes, 
we checked the level of FLT3 transcript in the cells by RT-PCR. We detected FLT3 
amplicon from both day 2 and day 7 cardiomyocytes (Figure 9b). We observed a decrease 
in the level of FLT3 expression from day 2 to 7 with similar expression level detected by 
the tissue array analysis. 
 
 
Figure 9 Detection of FLT3 expression from iPSC-derived human cardiomyocytes a) iPSC-derived 
human cardiomyocytes were thawed and stained with anti-human FLT3 antibody or with isotype control on the 
cell surface and intracellularly to detect FLT3 expression on day 2 and day 7 after thawing. MFI values of each 
sample is listed in the table. b) RNA was isolated from iPSC-derived cardiomyocytes on day 2 and day 7 after 
thawing. FLT3 is amplified by RT-PCR to detect the mRNA. We observed a decrease in the intensity of FLT3 
expression from day 2 to day 7. THP1 cells served as a positive control for FLT3 expression and GAPDH was 
amplified as internal control. 
4.4.3. Detection of FLT3 in primary human brain tissues 
To elucidate whether we can detect FLT3 expression in primary human cerebellum, 
we isolated RNA and protein from snap frozen cerebellar tissue of three different donors. 
In accordance with the observation we had from nerve tissue cDNA array, we detected 
FLT3 amplicon from cerebellar vermis of two donors and cerebellar hemisphere of all 
donors. We did not detect significant FLT3 expression in the frontal lobe, which served as 
a negative control (Figure 10a). Next, we separated total protein lysate from each sample 
by SDS-PAGE and immunoblotted to see whether we could detect FLT3. We observed 
two bands from THP1 protein lysate as expected. The upper band at 160 kDa level 
corresponds to glycosylated, mature FLT3. This form of FLT3 is found in the plasma 
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membrane where it functions as a tyrosine kinase receptor. The lower 145 kDa band is 
the ER-bound immature FLT3 which is retained intracellularly. We detected only 145 kDa 
band corresponding to immature FLT3 from cerebellar vermis and hemispheres 
suggesting it is found primarily intracellular (Figure 10 b).  
 
 
Figure 10 FLT3 expression in primary human brain tissues a) FLT3 transcript was detected in cerebellar 
vermis and hemispheres. GAPDH served as the internal control for the RT-PCR reaction. b) Total protein 
lysate of the same sections were seperated by SDS-PAGE. Immunoblotting revealed presence of ER-
associated, intracellularly retained FLT3 in both cerebellar vermis and hemispheres. Protein lysate from THP1 
cell line served as positive control where we detected both 160 kDa membrane associated FLT3 and 145 kDa 
ER-associated FLT3.  
To investigate which cerebellar cell type expresses FLT3 and its subcellular 
localization, we did immunohistochemical (IHC) (Figure 11A-F) and immunofluorescence 
(IF) (Figure 11G-L) stainings of cryo-sectioned cerebellar tissue. In Figure 11 A-B, granular 
layer (GL) and molecular layer (ML) of the cerebellum can be seen. Strong expression of 
calbindin, an intracellular, Purkinje-specific marker, was detected showing Purkinje cells 
residing between those layers (arrows). Additionally, the sections were co-stained with a 
neuronal membrane marker, CD56 (NCAM). IHC staining with an anti-FLT3 antibody 
yielded strong FLT3 expression in the Purkinje neurons confirming the PCR and western 
blot analysis. To investigate subcellular localization of FLT3 in Purkinje cells (PCs), we 
analyzed the IF staining with confocal microscopy. We observed FLT3 expression (red) in 
the cytoplasm of the PCs. Co-localization of CD56 (green) and FLT3 on the plasma 
membrane was not detected indicating FLT3 expression is dominantly intracellularly-
restricted (Figure 11H-L). This observation, in accordance with the western blot, 
suggested that FLT3 is found primarily intracellularly in PCs of human cerebellum. 
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Figure 11 Immunohistochemical (IHC) (A-F) and immunofluorescence (IF) (G-H) stainings of human 
cerebellar sections. Purkinje cells, that were stained against Calbindin, lay in between the granular layer 
(GL) and molecular layer (ML) (A-B, arrows). Double IHC staining shows strong calbindin expression in the 
cytoplasm (C,D), membrane bound expression of CD56 (NCAM) (C-F) and intracellular expression of FLT3 
(E-F, arrow). Confocal microscopy with double IF staining shows CD56 (G-L, green) is localized on the cell 
membrane while FLT3 (G-L, red) is present in the cytoplasm of the cell. Co-localisation of CD56 and FLT3 (L, 
arrows) was not detected indicating FLT3 expression is restricted to intracelliular compartment of Purkinje 
cells  
 




In this work, TCRs against epitopes of human FLT3 were isolated from a non-tolerant 
host, characterized and evaluated as potential therapeutic TCRs to be used in the context 
of an HLA-A2 mismatch allogeneic-HSCT for HLA-A2+ patients with relapsed or therapy 
resistant AML. The ABabDII mouse model was employed to raise high-affinity TCRs as a 
non-tolerant host to avoid central tolerance. This murine model has helped to generate a 
number of high-affinity TCR against human self-antigens in the past 10 years as discussed 
later in this chapter. We can provide definitive evidence that one of the selected epitopes 
is naturally processed and presented, although the identified TCRs did not have optimal 
affinity for efficient target cell recognition. Most importantly, and to our surprise, we 
demonstrated that FLT3 expression is not restricted to the hematopoietic cell 
compartment; therefore, we did not proceed with the attempt to develop a higher-affinity 
TCR against this antigen. In our opinion, the expression of FLT3 in regions of the human 
brain, and particularly in the Purkinje cells of cerebellum preclude the use of a high-affinity 
TCR because of potential serious on-target toxicity against vital tissues. 
5.1. Characterization of FLT3-specific TCRs raised in 
ABabDII mice 
5.1.1. Identified epitopes are immunogenic in ABabDII mice 
The ABabDII mouse is a good platform to generate high-affinity TCRs against human 
self-antigens that are not 100% homologous to the murine counterparts. This mouse 
model, published in 2010, is knock-out for murine TCR  and  genes, transgenic for the 
entire human TCR  and  gene loci and expresses a single human MHC-I allele HLA-A2 
with a mouse CD8 binding domain (HHDII). These mice can rearrange human TCRs and 
positively select them on the human HLA-A2 allele generating a diverse T cell repertoire. 
As a proof of concept, ABabDII mice were immunized with HLA-A2-restricted epitopes 
derived from eight human TAAs which are Melan-A, tyrosinase, α-fetoprotein, gp100, 
melanoma-associated antigen-A1 (MAGE-A1), MAGE-A10, cancer-testis antigen NY-
ESO-1 and six-transmembrane epithelial antigen of the prostate (STEAP). All mice 
developed CD8+ T cells responses against the epitopes showing the usability of the 
ABabDII model for the identification of CTLs against human self-peptides.79 Furthermore, 
a clinically relevant, high-affinity TCR targeting MAGE-A1 was identified, which has a 
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higher avidity compared to TCRs identified from a tolerant human repertoire showing the 
value of the mouse model to pull therapeutic TCRs.80 
FLT3 has a mouse homolog, thus, to elicit a response in the ABabDII mice, we selected 
epitopes with at least two amino acid differences in the peptide sequence compared to the 
mouse protein. The 9-mer FLT3839 epitope (IMSDSNYVV) has two amino acid differences 
compared to the mouse homolog. The mouse epitope bears a Leucine instead of the 
Methionine at the 2nd position (ILSDSSYVV, Figure 1a). The anchor residues at the 2nd 
and 9th position of a 9-mer epitope facilitate binding to the HLA-A2 molecule, and therefore, 
has an impact on the peptide-binding affinity.118 There is a higher preference for an L 
residue at the 2nd position followed by a preference for an M residue.119 Thus, the murine 
counterpart of the sequence has similar predicted binding affinity as human FLT3839. The 
amino acid change from an N to S at the 6th position should be enough for this epitope to 
be foreign to the mice repertoire, therefore, it is reasonable to expect an immune response. 
Indeed, the strong peripheral response observed in mouse 6547 immunized with FLT3839 
confirms the immunogenicity of this epitope. The other 9-mer epitope selected, FLT3986 
(GLLSPQAQV), shares 6 amino acids with murine FLT3 (EPPSPQAQV). The ABabDII 
model is unlikely to have tolerance to the human epitope because the murine sequence 
has extreme low predicted binding affinity to HLA-A2 (38887.75 nM) making it unlikely to 
be presented by thymic cells to trigger any negative selection. We detected IFN- 
production by the peripheral CD8+ T cells of mice 6547 and 6782 immunized with either 
FLT3839 or FLT3986 peptide, respectively. Although the other two mice did not exhibit 
peripheral response, there were peptide reactive T cells in the spleen that could be 
expanded in vitro for subsequent TCR identification. These responses indicate that both 
epitopes were immunogenic in ABabDII mice and could develop high affinity TCRs against 
FLT3839 and FLT3986.  
5.1.2. FLT3986 is naturally processed and presented by K562 cells 
The TCRs that were identified from the ABabDII mice recognize their respective 
epitopes when exogenously loaded on T2 cells (Figure 3). To analyze whether these 
epitopes are naturally processed and presented, we tested the TCRs on K562 cells that 
express both the FLT3 antigen and the HLA-A2 allele. K562 cells normally lack expression 
of class I and class II molecules on the surface. Yet, they retain the ability to present 
antigens to CD8+ T cells once transduced with an MHC-I allele because they express 2m 
molecule.120 This makes K562 cells a good test platform to detect antigen-specific CD8+ T 
cell response restricted to single allele, while avoiding background activation induced by 
other alleles. Human PBLs transduced with the 6780-GLL TCR recognized K562 cells 
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expressing HLA-A2 and FLT3 proving that the FLT3986 epitope is processed by the cell 
machinery and presented by HLA-A2. However, we could not detect any IFN- secretion 
from PBLs transduced with 6782-GLL TCR (Figure 4a). This might be due to a low 
functional avidity of 6782-GLL TCR, as suggested by the observation that it secretes less 
IFN- compared to 6780-GLL in the peptide titration assay (Figure 3a). Yet, although there 
is no recognition of K562-A2-FLT3 cells by 6546-IMS TCRs, it is not possible to draw 
definitive conclusions on processing and presentation of the other epitope, FLT3839. K562-
A2 cells loaded with high concentrations (1 M) of FLT3839 peptide were also not 
recognized suggesting that this could be due to a low functional avidity of the TCR rather 
than to the lack of peptide availability. In other words, 6546-IMS TCR seems to have such 
a low avidity that it wouldn’t recognize the target cells even if the FLT3839 peptide would 
be naturally processed and presented. 
5.1.3. FLT3986 presentation by the AML cell line THP1 is not 
sufficient for efficient T cell recognition 
Knowing the FLT3986 peptide is naturally processed and presented, we tested the 
FLT3986-specific TCRs on three cell lines which express FLT3 endogenously. THP1 is an 
AML cell line that is often used in studies focusing on FLT3 function in AML and evaluating 
it as an AML target. It is homozygous for the HLA-A2*01 allele with high level of HLA-A2 
expression on the cell surface making it a valuable and efficient model for testing the FLT3-
specific TCRs. Unfortunately, we could not detect any IFN- release or CD137 
upregulation on TCR-transduced CD8+ T cells after overnight co-culture with THP1 cells. 
It could be argued that the lack of T cell response could be due to deficient peptide 
processing and presentation machinery of this cell line. However, when THP1 cells 
overexpressing FLT3 were used as target cells, we detected CD137 upregulation on 6780-
GLL TCR-transduced T cells which can be interpreted as the processing machinery of the 
cell line is functional. 
One potential explanation for the lack of response to unmodified THP1 cells could be 
the sub-optimal avidity of both of our FLT3986-specific TCRs. First, we need to make clear 
distinction between the terms TCR affinity and avidity. TCR affinity is defined as the 
binding strength of one TCR molecule to a pMHC complex. The binding kinetics of TCR-
pMHC interaction is measured by surface plasmon resonance (SPR) using soluble TCRs 
and immobilized pMHC complexes to calculate a KD value.121 The KD values of high-affinity 
TCRs lay in the range of 1-50 µM,121 however, this parameter cannot be used to compare 
our TCRs with known high-affinity TCRs because such experiments were not performed 
on our TCRs. 
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 TCR avidity, on the other hand, is assessed by the cytokine release upon stimulation 
with pMHC complexes and target cell lysis. The peptide concentration required to reach 
half-maximal IFN- release, called EC50, is a good estimate of TCR avidity.122 The EC50 of 
6780-GLL TCR, which is in the nanomolar range, might be too low for recognizing target 
cells in physiological conditions. The ABabDII-derived MAGE-A1 TCR has an EC50 value 
in the picomolar range.80 Likewise, an HLA-B7 restricted MPO1-specific TCR identified 
from an allogeneic repertoire has 150 pM EC50.112 Both those TCRs that were identified 
by different approaches efficiently recognize target cells. The lower EC50 value indicates 
higher avidity meaning TCRs require lower antigen density for target cell recognition.122. 
Activation of 6780-GLL TCR, that has the highest functional avidity, probably requires a 
higher density of FLT3986-HLA-A2 complexes on the surface than the THP1 cells have. In 
fact, overexpression of FLT3 in THP1 cells resulted in activation of 6780-GLL TCR 
transduced T cells as detected by CD137 upregulation on 25.33% of the TCR-tranduced 
T cells. Based on these observations, it is likely that the avidities of 6780-GLL and 6782-
GLL TCRs are not sufficient to recognize the FLT3986-HLA-A2 complex at physiological 
level on an AML cell line. 
5.1.4. FLT3986-specific TCR can recognize cells with both wild 
type FLT3 and FLT3-ITD mutation 
SEM and MV;4-11 cells express a high level of FLT3. HLA allotypes of SEM and 
MV4;11 are A01:01, 32:01; B08:01, 15:01; C03:03 07:01 and A68:01, 03:01; B14:02, 
18:01; C15:02, 08:02, respectively.123 In other words, neither of the cell lines express HLA-
A2 endogenously. Both cell lines were recognized by 6780-GLL TCR after viral delivery of 
HLA-A2 proving that the level of HLA-A2 and FLT3 expression was sufficient to reach a 
pMHC density on the surface that is able to interact and trigger TCR-mediated activation. 
MV4;11 has lower FLT3 on the cell surface compared to SEM, yet induced similar degree 
of T cell activation (Figure 5b). This cell line is an FLT3-ITD mutant, which interferes with 
FLT3 glycosylation pattern preventing its transport from the ER to the cell membrane, while 
SEM and THP1 cells express wild type FLT3. Although it was not experimentally shown 
in this work, MV4;11 cells still retains high FLT3 level in the cell due to the mutation, 
explaining the T cell activation. The internal tandem duplication (ITD) in the 
juxtamembrane domain (JM) domain of FLT3 causes constitutive activation of FLT3. This 
gain-of-function mutation is responsible for enhanced proliferation and survival of AML 
blasts, which is observed in 24% of AML cases, classifying them as high-risk AML.124 The 
patients carrying this mutation are not eligible for some of the novel FLT3-specific 
therapeutics when these require surface FLT3 expression such as in the case of CAR-T 
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cells. TCRs, on the other hand, do not rely on surface expression of the target antigen, 
being able to recognize epitopes derived from cellular proteins. Even though 6780-GLL 
TCR has low avidity, it also recognized MV4;11 cells carrying FLT3-ITD mutation 
suggesting that FLT3-specific TCRs could be superior to CAR-T cells in eradicating FLT3-
ITD mutant AMLs. 
5.1.5. K562 cells are a good model for initial screening of TCRs 
We detected IFN- release only against retrovirally modified K562 cells expressing 
FLT3 and HLA-A2 molecule. The other target cell lines induced some degree of T cell 
activation as indicated by phenotype changes, but that was not sufficient to trigger a 
detectable level of IFN- secretion. Although K562 cells that have both the antigen and the 
restriction element is a good model to screen TCRs initially, it does not properly mimic 
antigen presentation by AML cells at physiological conditions and therefore does not 
guarantee that the TCR will be clinically relevant. There could be multiple reasons for this. 
First, both transgenes were delivered with a -retroviral vector. It is very likely that multiple 
viral integration events happen upon transduction, which insert multiple copies of the 
transgenes in the K562 genome, and yielding much higher expression levels of the 
proteins than is normally observed in AML cells. Second, the strong cis-regulatory 
elements of pMP71 vector, that drive the expression of the transgenes, contributes to a 
high level of protein accumulation in the cell.125 Third, K562 cells normally do not express 
any MHC-I molecule, whereas each nucleated cell in the body bears up to 6 different MHC-
I alleles on the cell surface.14 Different MHC class I alleles compete with each other for 
expression on the cell surface,126 probably through competition for 2m,127 the presence 
of other alleles may negatively affect the presentation by a particular allele. K562 cells 
transduced to express HLA-A2 might have only this one allele on the surface at a much 
higher density as compared to normal cells carrying multiple HLA-alleles. If this is the case, 
K562-A2 cells most likely present HLA-A2 restricted epitopes much more efficiently as 
compared to the other cell lines used in this study, which have the normal repertoire of 
several different HLA molecules. However, to support this, K562 cells carrying multiple 
alleles must be generated and tested for their differences in peptide presentation capacity 
on HLA-A2. This feature can be very useful when screening for a particular TCR reactivity, 
but can lead to wrong conclusions concerning the physiological density of peptide-MHC 
complexes as compared to normal cells or tumor cells. 
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5.1.6. CD8-dependence of FLT3986-specific TCRs does not 
correlate with their avidities 
CD8 is the co-receptor of MHC class I-restricted TCRs and expressed on cytotoxic T 
cells. The main function of this co-receptor is to stabilize the TCR-pMHC binding.128. By 
enhancing the duration and stability of TCR-pMHC interaction and recruiting signaling 
elements such as Lck, CD8 potentiates T cell activation. However, it has been shown that 
not all class I TCRs are CD8 dependent. TCR affinity to the pMHC plays a crucial role 
here. Current understanding of TCR-pMHC dynamics postulates that higher affinity TCRs 
bind to the pMHC stable enough and may not require CD8-mediated stabilization. 
Therefore, CD8-independent TCRs are expected to have higher affinity and better avidity. 
129 Tetramers are multivalent complexes of biotinylated soluble pMHCs and a streptavidin 
molecule that has four biotin binding sites.130 Those pMHC tetramers can be conjugated 
to fluorophores, which enables easy detection of TCR-pMHC binding using flow cytometry. 
Additionally, cells can be stained simultaneously for cellular markers to deduce more 
information on cell type and functional characteristics of the particular antigen-specific T 
cell population. Co-staining of transduced PBLs with an anti-CD8 antibody and pMHC 
tetramer showed 6782-GLL TCR does not require CD8 molecule to bind to the tetramer. 
Whereas in the case of 6780-GLL and 6546-IMS, none of the CD8- cells were bound to 
the tetramer. This suggests 6782-GLL is CD8 independent and should have highest affinity 
and avidity, However, the avidities of the FLT3986-specific TCRs do not correlate with the 
CD8-coreceptor dependence. According to the peptide titration and target cell recognition 
data, 6780-GLL has the best avidity, yet, it requires CD8. We did not do further 
experiments to clarify the reason of contradiction with the current knowledge because the 
study on these TCRs were dropped due to safety profile discussed later.  
5.1.7. Poor presentation of FLT3986 by leukemic cells is likely due 
to low pMHC affinity and stability  
It is known that TCR affinity to a cognate pMHC complex is an important parameter for 
efficient target cell recognition and killing. However, this is not the only parameter to 
consider. First, the affinity of a peptide to a certain MHC-I allele is a very important 
criterium.131 Early studies on peptide presentation to I T cells have proven that the peptides 
compete with each other for MHC-I binding and cell surface presentation.132,133 It has been 
experimentally shown that the addition of a peptide with a high binding affinity can block 
or prevent the presentation of a peptide with lower affinity resulting in loss of 
recognition.132,133 FLT3986 has a low predicted affinity to HLA-A2; thus, it is highly possible 
that it is not very efficiently presented due to competition with higher-binder epitopes 
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derived from other antigens even though it is processed by the cells. This can explain the 
lack of THP1 recognition in our experiments. It has been shown that higher gene 
expression and protein abundance in the cell correlates with enhanced presentation of a 
particular antigen.134,135 In line with this, we found that overexpression of FLT3 on THP1 
cells can rescue target cell recognition by TCR-transduced T cells. The higher availability 
of FLT3 in the cell might likely have increased the density of FLT3986-MHC-I ligands on the 
cell surface leading to target cell recognition despite the fact that the epitope is predicted 
to be a low-binder. Similarly, K562-A2-FLT3 are efficiently recognized most likely due to 
supra-physiological HLA-A2 ligand density on surface. Second, the affinity of a peptide to 
an HLA molecule alone is not sufficient to predict immunogenicity: not all peptides with 
high binding affinities to MHC-I are equally immunogenic, it is rather the stability of the 
pMHC complex that correlates better with the magnitude and strength of ICD8+-T cell 
response.136 A tool was developed after our study design incorporating the stability of 
pMHC-I to the prediction of immunogenicity called NetMHCstabpan.137 FLT3986 was 
predicted to have low stability with 2.09 hours half-life meeting the minimum requirements 
to be immunogenic but not sufficient to evoke efficient T cell activation possibly explaining 
the lack of recognition at physiological levels of gene expression. Knowing that the optimal 
epitope binding affinity for tumor rejection and long-term control is below 10 nM, whereas 
intermediate binders (IC50 between 50 and 500 nM) and low binders (IC50 > 500 nM) are 
associated with relapse, we can conclude that although being processed and presented, 
FLT3986 seems not to be suitable as a rejection epitope for clinical application.131,138 Both 
the low affinity of FLT3986 to HLA-A2 molecule and the low predicted stability of FLT3986-
HLA-A2 complexes indicate that this epitope is not suitable to induce efficient target cell 
recognition. 
Search in the IEDB database for experimentally-identified HLA-A2-restricted FLT3-
restricted high-binders reveals a 9-mer (SLFEGIYTI) eluted from the immunopeptidome of 
BV173 cells by MS while neither of the epitopes targeted in this study were detected.139 
This peptide is predicted to have 2.93 nM affinity (NetMHC 4.0) to HLA-A2 and high 
stability with 11.97 h half-life (NetMHCstab) fulfilling the requirements for ideal tumor-
rejection epitope. However, its 100% homology to murine FLT3 restrained us from 
immunizing the ABabDII mice with it because of the likelihood of central tolerance against 
it. Allogeneic in vitro T cell priming could have been a way to avoid the tolerance against 
SLFEGIYTI but we did not follow that approach for the reasons discussed in the next 
section. 
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5.2. FLT3 expression in human tissues 
5.2.1. FLT3 is present in non-hematopoietic tissues 
We selected FLT3 as target antigen for the ACT of TCR-engineered T cells for the 
treatment of hematological malignancies, in particular AML, due to its high expression in 
hematopoietic progenitor cell and AML blasts. Several groups cloned FLT3 in the early 
‘90s and identified it as a hematopoiesis-specific antigen specifically expressed in early 
stage CD34+-HSCs.140–142 In mouse, flt3 expression was initially detected by northern blot 
in fetal liver, fetal brain, adult brain, and bone marrow.140 Western blot analysis of several 
fetal and adult mouse tissues revealed the presence of the protein in adult mouse brain, 
cerebellum, placenta, spleen and thymus.143 In humans, tissue distribution of FLT3 was 
not studied thoroughly. It was detected in fetal liver, spleen and thymus by PCR. In adult 
tissues, the expression was predominantly in lympho-hematopoietic compartment such as 
bone marrow, spleen, monocytes, and granulocytes. The transcript was detected 
placenta, however, it was the only non-hematopoietic adult tissue that was analyzed.141 
Accordingly, FLT3 was long considered to be a lineage specific marker of hematopoiesis. 
Early studies on human samples indicated it could be safe to target FLT3 with a high-
affinity T cell receptor due to its tissue-restricted expression. However, in the ‘90s, the 
technology to detect gene expression was limited with low sensitivity and the variety of the 
human tissues analyzed was not high. Therefore, to ensure the safety of targeting FLT3, 
in parallel to our effort to generate high-affinity TCRs, and in view of the unexpected toxicity 
of some TCRs thought to be tumor specific in clinical studies,70,71,144 we initiated an 
extensive analysis of FLT3 expression in human tissues. We employed a cDNA array 
representing 48 major healthy human tissues. As expected, FLT3 transcript was detected 
from the bone marrow, lymph node, lymphocytes, spleen, thymus and tonsil, in line with a 
distribution of the antigen within the hematopoietic and lymphoid compartment. We 
detected faint FLT3 expression in some non-hematopoietic tissues which are the left 
ventricle of the heart, lung, prostate, skin and pancreas. We speculated the source of the 
transcript in some probes, such as the left ventricle of the heart could be due to 
contaminating blood cells as the tissues used to prepare the cDNA array was reported not 
to be washed out by NaCl perfusion by the manufacturer. However, in one study FLT3 
was detected in adult mouse cardiomyocytes both at transcript level and on the surface 
by FACS.117 This led us to investigate FLT3 expression in iPSC-derived human 
cardiomyocytes. Unlike Pfister et al., we detected very low level of the transcript, which is 
consistent with the results of the cDNA array; but could not find protein expression (Figure 
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9). The expression in the lung and the pancreas can be attributed to the tissue resident 
DCs in those tissues. 
The tissue array that was initially evaluated included two neuronal tissues; brain and 
spinal cord. We observed faint FLT3 amplicon from both of those tissues which prompted 
us to investigate whether other neuronal tissues express FLT3. For this purpose, we 
amplified FLT3 from a cDNA tissue array representing 24 different anatomical brain 
regions. We observed FLT3 expression in different sections ranging from very faint in the 
Substantia nigra to very high in cerebellar sections. Our results were supported by the 
GTEx and FANTOM5 RNA sequencing datasets that pinpointed presence of significant 
FLT3 mRNA in human cerebellum.145 All these observations are consistent with an older 
report from De Lapeyriere et al.,143 showing the presence of Flt3 expression in adult mouse 
hematopoietic and nervous tissues. These authors had detected faint Flt3 expression by 
in situ hybridization in different brain sections of adult mice but intense expression in 
cerebellar tissue. They reported FLT3 presence in the form of a 145 and a 160 kDa protein 
band in mouse lymphoid tissues, while only a 145 kDa protein band was found in brain 
and cerebellar tissues.143 The authors argued that the function of FLT3 might be different 
in nervous tissues as compared to hematopoiesis but did not provide evidence for this.146 
Later, another study showed presence of Flt3 in mouse neuronal progenitor cells, 
confirming the expression in some differentiated neurons in mouse brain again reaching 
the highest level in cerebellar Purkinje cells. The authors also showed that the mouse 
neurons respond to FLT3L by stopping cell division. This finding is intriguing since this 
behavior is completely different from the response of hematopoietic cells where FLT3L 
binding mediates activation and proliferation.147 
To investigate whether FLT3 transcript is translated in human neuronal tissues, we set 
out to obtain cerebellar samples from post-mortem individuals with healthy cerebellum. 
We started by detecting FLT3 amplicon from the RNA isolated from the cerebellar vermis 
and hemispheres to confirm the observation from the tissue array. Western blot analysis 
of protein lysates from the same tissue sections indicated the presence of a 145 kDa band 
from both regions of the cerebellum confirming the presence of the protein in this tissue. 
FLT3 has a molecular mass of 145 kDa in its immature form and is found intracellularly 
associated with the endoplasmic reticulum (ER). During maturation, it is glycosylated with 
N-linked carbohydrates in the Golgi apparatus. This mature form with approximately 160 
kDa mass is transported to the plasma membrane and corresponds to the functional FLT3 
variant.148 The size of the band detected in cerebellar sections suggests that FLT3 might 
be present intracellularly in the cerebellar neurons. Since we did not detect the higher 
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molecular weight band, it could be speculated that the glycosylated, membrane associated 
form is not synthetized in the cerebellum. 
5.2.2. Purkinje cells in human cerebellum can be a site for on-
target toxicity 
As a further step, and because of the important clinical implications, we examined 
which cell type expresses FLT3 in the human cerebellum and whether cerebellar FLT3 is 
present on the cell surface or possibly only intracellularly as might be speculated on the 
basis of western blots. IHC stainings of sections revealed that Purkinje cells in human 
cerebellum express FLT3 intracellularly. The cell type that expresses FLT3 overlaps with 
the earlier mouse studies. Nevertheless, subcellular localisation of FLT3 in Purkinje cells 
was not reported before and is shown for the first time in this study. Purkinje cells are the 
largest neurons in the human brain and belong to a class of GABAnergic neurons located 
in the cerebellum. They integrate afferent signals mainly from the brainstem and send their 
axons down to the deep cerebellar nuclei.149 On-target recognition of Purkinje cells by 
TCR-transduced T cells with consequent cellular damage may induce serious 
complications since Purkinje cell degeneration causes coordination deficits, such as limb 
ataxia, dysarthria, and oculomotor disturbances, as seen in some paraneoplastic 
syndromes, where autoantibodies to Purkinje cells have been demonstrated.150  
TCR-modified T cells recognize epitopes derived from cellular proteins presented on 
MHC-I molecules independent of the cellular localisation of the antigen. Having shown that 
Purkinje cells have intracellular FLT3, peptides derived from proteasomal digestiong of the 
protein may be presented on MHC-I molecules of these cells to the T cells. TCRs are very 
potent and have been shown to recognize target cells bearing as low as 10 pMHC 
complexes on the surface.151,152 The human brain is considered to be an immune priviliged 
site, there are some reports on the absence of MHC class I molecules in adult human 
brain.153 However, a study from 2014 showed expression of 2m in neurons in the 
Substantia nigra and the locus coeruleus. They detected mRNA of MHC class I molecules 
as well as MHC-derived peptides by mass spectrometry. Furthermore, it was shown that 
IFN- treatment induces MHC-I expression on human embryonic stem cell (hES)-derived 
dopaminergic neurons in vitro.154 Even if there is contradictory evidence, it is possible that 
MHC-I expression, epitope presentation and T cell activation may happen simultaneously 
in human brain leading to CTL activity against Purkinje cells. In the light of these finding, 
and considering the neurological toxicity that was observed in the MAGE-A3 trial,70 we 
concluded that the risk of using an FLT3-specific TCR is unaceptable in our opinion. 
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Therefore, we stopped our efforts to generate new TCRs with improved affinity and better 
recognition of FLT3: it is most likely that such reagents would never come to clinical use.  
5.3. Evaluating FLT3 as a target for AML-specific TAA 
Since the success of CAR-T cells targeting CD19 in the clinic, there has been growing 
interest in developing cellular therapeutics targeting AML antigens such as CD33 and 
CD123. Because of its high and uniform surface expression on the majority of AMLs,155 
FLT3 is a very attractive target for CAR-T cells. The first report on FLT3-specific CAR-T 
cell was published in 2016 shortly after our work had been initiated, showing that FLT3-
CARs recognize AML-derived cell lines. Indeed, it was reassuring for us, that other groups 
were targeting the same antigen, although with a different strategy. The authors observed 
low-level toxicity to CD34+ HSCs as decreased monocyte counts in a NSGS mice model 
engrafted with CD34+ human cord blood cells.156 Conversely, in 2017, Chen and 
coworkers reported a another FLT3-CAR with promising activity against leukemic cells 
and no apparent toxicity on HSCs in the same mouse model engrafted with CD34+ human 
cord blood cells.157 In 2018, two more studies were published. One group followed a 
different approach and developed an FLT3-Ligand-based CAR. They showed their CAR-
T cells recognize target cell lines with both wild type FLT3 and FLT3-ITD mutation and did 
not observe any reduction in the colony formation of CD34+ human cord blood cells upon 
co-culture with FLT3L-CAR T cells stating the CAR does not have toxicity against HSCs.158 
Last but not least, Jetani and colleagues developed another FLT3-CAR derived from an 
FLT3-specific antibody clone 4G8SDIEM with detectable HSC toxicity.159 They showed 
that in a FACS based-cytotoxicity assay FLT3-CAR T cells lyse 50% of GM-CSF mobilized 
human CD34+ HSCs in 4 hours. Furthermore, they observed depletion of HSCs in a 
human HSCs-grafted NSG-3GS mouse model after treatment with FLT3-CAR.159 
Nevertheless, this antibody clone was previously evaluated both in vitro on human HSCs 
and on human subjects without evidence for toxicity related to recognition by the 
antibody.160,161 The same antibody clone was used to develop an FLT3xCD3 bi-specific 
antibody that did not have any toxicity to HSCs in an colony forming assay of HSCs 
obtained from three healthy donors, which was the only cell type that was tested against.162  
Case reports on application of TCR- or CAR-T cells showed the risk and seriousness 
of TCR- and CAR-T cell related on-target toxicities ranging from mild to fatal side 
effects.69,71,144,163–165 Despite these examples, all of the studies mentioned above focused 
on potential on-target toxicity on HSCs based on the current knowledge on FLT3 
expression in human tissues. According to data published, none of those groups 
investigated FLT3 distribution on other tissues, nor did they test the antibody or CAR-T 
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cells for reactivity against other tissues. We detected FLT3 expression in iPSC-derived 
cardiomyocytes. Although the level was very low and not detectable on cell surface by 
FACS, testing CAR-T cells first in vitro on suitable models would be strongly recommended 
to prevent any serious complications in human subjects. 
All these studies are consistent with advantages and drawbacks of antibody-based 
therapies such as CAR T cells compared to TCR based therapies: antibodies recognizing 
different epitope on a cell surface protein might have completely different biological effects, 
and even antibodies recognizing the same epitope might have very different effects, based 
on the affinity of the antibody. Paradoxically, while the most potent reagent is considered 
to be the best for immunotherapeutic approaches, a weaker antibody might be clinically 
better suitable, when the antigen is present on normal cells at a weaker extent. Possibly, 
such antibody would not exhibit toxicity that might instead occur when the antibody has 
strong activity potentially recognizing and killing even cells with a weak antigen expression. 
So, a weaker antibody that kills tumor might be harmless to normal tissue, while a potent, 
more effective antibody may induce severe toxicity to healthy tissue. In other words, it is 
possible to “tune” the activity of an antibody (and of all antibody-derived tools such as 
bispecific antibodies and CAR T cells), while this most likely might be very difficult when 
using TCR based strategies. Although differences in the TCR affinity might have different 
clinical activities, this might be much more difficult to modulate, considering that T cell 
activation in vivo and cytokine release by the microenvironment might be able to influence 
the level and abundancy of MHC-I molecules, a critical parameter for T-cell recognition, 
as our own study here indicated. 
While the presence of FLT3 in Purkinje cells might cause on-target toxicity when it is 
targeted with a TCR, in the case of FLT3-specific CAR-T cells, the cerebellar on-target 
toxicity may be of less concern because of the localization of FLT3 in Purkinje cells, which 
appear to be mainly cytoplasmic and therefore could not be available for antibody 
recognition. Nevertheless, in our opinion it would be strong recommended to test the CAR-
T cells on neural tissues such as the cerebellum, pons and spinal cord to ensure the safety 
of the FLT3-specific CAR-T cells before moving to a clinical study in human subjects. 
5.4. Prospects on targeting AML with TCRs 
We identified three TCRs targeting two different HLA-A2-restricted epitopes derived 
from human FLT3. None of those TCRs had enough functional avidity to be used in the 
clinic leaving space for further efforts to identify better epitopes and higher-affinity TCRs. 
However, we restrained from further efforts as we detected FLT3-transcript in non-
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hematopoietic tissues, particularly brain. It was shown that neuronal stem cells (NSCs) 
can differentiate into different types of blood cells when grafted to the bone marrow of 
irradiated Balb/C mice bringing the attention the high degree of similarity between these 
distinct tissues.166 In other words, identification of safe, hematopoiesis-restricted TAAs 
could be rather challenging. 
As we have learned from this study, all kind of tissues have to be examined and tested 
extensively before and during antigen selection and TCR identification. As an alternative 
to the search for AML-specific TAAs, more focus can be put on identification of truly cancer 
specific, shared TSAs. Two separate groups studied the mutant immunopeptidome of AML 
to identify targetable neoantigens. Collectively, they have identified two HLA-A2-restricted 
(CLAVEEVSL and a cysteinylated version C*LAVEEVSL) and an HLA-A*3:01-restricted 
(AVEEVSLRK) neoepitopes derived from Nucleophosmin 1 (NPM1) mutation, which is 
found in 27-35% of adult AML.167,168 Van der Lee et al. have detected CD8+ T cell 
responses against HLA-A2-restricted neoepitopes from healthy donors. They 
demonstrated T cells engineered to express a C*LAVEEVSL-specific TCR can lyse 
NPM1-mutant AML cells while sparing NPM1-WT AML in vitro and control leukemia in vivo 
xenograft model.167 Similarly, in our group we identified HLA-B7-restricted TCRs against 
MyD88 L265P-derived neoantigens from the periphery of healthy individuals. MyD88 
L265P is a shared mutation found in 20% of all lymphoid malignancies and can be used 
to target diffused B cell lymphomas (DLBCL), primary CNS lymphomas and 
Waldenström’s macroglobulinemia as well as some cases of chronic lymphocytic leukemia 
that also present this mutation. The TCRs were shown to recognize mutant MyD88 DLBCL 
cell lines in vitro and the preclinical characterization is still ongoing.169 These studies are 
encouraging examples for the search of targetable shared or private AML-specific 
neoantigens. 
The discoveries accumulating since decades in the field of cancer immunology and T 
cell biology have deepened our understanding of T cell response against tumors. In the 
future, safer AML-specific TAAs and TSAs could be identified with the help of the 
advancements in the tools that are used to explore immunopeptidome, such as mass 
spectroscopy and prediction algorithms, as well as through the improved methods to raise 
potent T cell responses. Finally, it is conceivable that combining the two approaches of 
immunotherapy, CAR T cells and TCR based adoptive T-cell therapy might compensate 
the limitation of both approaches which have been shortly discussed here, including 
surface modulation of the CAR target and MHC downregulation of the TCR-epitope. 
Simultaneous or sequential administration of these different cellular products, CAR and 
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TCR- gene modified T cells eventually in conjunction with small molecule selectively 
inhibiting oncogenic pathways, might be able to finally eliminate any residual leukemic 
cells, possibly eradicating the disease and making chemotherapy obsolete. 
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6. Summary 
Acute myeloid leukemia (AML) is a disease with poor prognosis. Fsm-like tyrosine 
kinase 3 (FLT3) is a promising target because of its overexpression in AML cells. Efforts 
have been put to develop new therapeutics targeting FLT3 by small molecule inhibitors 
and most recently with chimeric antigen receptor (CAR) modified T cells. We generated 
HLA-A2-restricted, FLT3-specific T cell receptors (TCR) to target FLT3-positive AML and 
hematopoietic stem cells (HSCs) in an HLA-A2-mismatched allogeneic-HSC 
transplantation. In our proposed set up, FLT3-specific TCRs would eliminate AML cells as 
well as HLA-A2-positive HSCs of the patient allowing engraftment of a healthy, HLA-A2-
negative hematopoietic system. FLT3 is a self-antigen, therefore, T cells bearing high-
affinity TCRs against epitopes derived from it are deleted in the thymus during T cell 
development. To circumvent the tolerance, we immunized a transgenic mouse model 
expressing a diverse human TCR repertoire and HLA-A2 molecule (ABabDII). The 
candidate epitopes for immunizations, FLT3839 and FLT3986, were selected among in silico 
predicted epitopes based on their binding affinity to HLA-A2 and homology to the mouse 
FLT3. We identified one TCR against FLT3839 (6546-IMS) and two TCRs against FLT3986 
(6780-GLL and 6782-GLL). IFN- release was detected only from 6782-GLL T cells after 
overnight co-culture with a K562 cell line that was modified to express high levels of FLT3 
and HLA-A2 proving FLT3986 epitope is naturally processed and presented. We tested the 
FLT3986-specific TCRs on three different cell lines that express FLT3 endogenously. We 
did not detect any CD137 upregulation by FACS or IFN- release by ELISA from neither 
of the FLT3986-specific TCRs against an AML cell line THP1. On the other hand, co-culture 
with SEM and MV-4;11 cell lines that express FLT3 endogenously and were modified to 
express HLA-A2 molecule, and with THP1 cells modified to overexpress FLT3 induced 
CD137 upregulation only on 6780-GLL T cells, but did not trigger any IFN- secretion 
suggesting higher FLT3 availability might be required for target cell recognition by the 
6780-GLL TCR. This could be due to i) the sub-optimal avidities of the identified TCRs to 
the pMHC complex ii) low binding affinity of FLT3986 epitope to HLA-A2 molecule resulting 
in a poor presentation on the cell surface. In addition, recognition of MV-4;11 cells which 
carry the FLT3-ITD mutation suggested FLT3986 epitope is produced from both the wild 
type and mutated FLT3. During the in vitro safety testing, we discovered high, intracellular 
FLT3 expression in the Purkinje cells of the human cerebellum. We have stopped our 
attempt to identify high-affinity FLT3-specific TCRs due to potential cerebellar toxicity. We 
believe FLT3 could still be a safe, valuable target for therapies other than TCR-modified T 
cells.  
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7. Zusammenfassung 
Die akute myeloische Leukämie (AML) ist eine Krankheit mit schlechter Prognose. Die 
Fsm-ähnliche Tyrosinkinase 3 (FLT3) ist wegen ihrer Überexpression in AML-Zellen ein 
vielversprechendes Ziel. Es wurden Anstrengungen unternommen, neue Therapeutika zu 
entwickeln, die auf FLT3 durch niedermolekulare Inhibitoren und in jüngster Zeit auch 
durch T-Zellen modifiziert mit dem chimären Antigenrezeptor (CAR) abzielen. Wir 
generierten HLA-A2-restringierte, FLT3-spezifische T-Zell-Rezeptoren (TCR), um FLT3-
positive AML und hämatopoetische Stammzellen (HSZ) in einer HLA-A2-inkompatiblen 
allogenen HSZ-Transplantation gezielt zu behandeln. In der von uns vorgeschlagenen 
Konstellation würden FLT3-spezifische TCRs sowohl AML-Zellen als auch HLA-A2-
positive HSZ des Patienten eliminieren, so dass ein gesundes, HLA-A2-negatives 
hämatopoetisches System transplantiert werden könnte. FLT3 ist ein Selbst-Antigen, 
daher werden T-Zellen mit hochaffinen TCRs spezifisch für Epitope von FLT3, während 
der T-Zellenentwicklung im Thymus deletiert. Um die Toleranz zu umgehen, haben wir ein 
transgenes Mausmodell immunisiert, das ein breites humanes TCR-Repertoire und das 
HLA-A2-Molekül (ABabDII) exprimiert. Die Epitop-Kandidaten für Immunisierungen, 
FLT3839 und FLT3986, wurden aufgrund ihrer Bindungsaffinität zu HLA-A2 und ihrer 
Homologie zu FLT3 der Maus unter den in silico vorhergesagten Epitopen ausgewählt. 
Wir identifizierten einen TCR gegen FLT3839 (6546-IMS) und zwei TCRs gegen FLT3986 
(6780-GLL und 6782-GLL). Die IFN- -Freisetzung wurde nur von 6782-GLL T-Zellen nach 
einer Co-Kultur über Nacht mit einer K562-Zelllinie nachgewiesen, die modifiziert wurde, 
um hohe Konzentrationen von FLT3 und HLA-A2 zu exprimieren, was beweist, dass das 
FLT3986-Epitop natürlich prozessiert und präsentiert wird. Wir testeten die FLT3986-
spezifischen TCRs an drei verschiedenen Zelllinien, die FLT3 endogen exprimieren. Bei 
keinem der beiden FLT3986-spezifischen TCRs konnten wir eine CD137-Hochregulierung 
durch FACS oder IFNgamma-Freisetzung durch ELISA gegen die AML-Zelllinie THP1 
nachweisen. Andererseits induzierte eine Co-Kultur mit SEM und MV-4;11 Zelllinien, die 
FLT3 endogen exprimieren und so modifiziert wurden, dass sie das HLA-A2-Molekül 
exprimieren, und mit THP1-Zellen, die so modifiziert wurden, dass sie FLT3 
überexprimieren, nur auf 6780-GLL T-Zellen eine CD137-Hochregulierung, löste aber 
keine IFN--Sekretion aus, was darauf hindeutet, dass eine höhere FLT3-Verfügbarkeit für 
die Erkennung der Zielzellen durch den 6780-GLL-TCR erforderlich sein könnte. Dies 
könnte auf i) die suboptimale Affinität der identifizierten TCRs zum pMHC-Komplex und ii) 
die geringe Bindungsaffinität des FLT3986-Epitops zum HLA-A2-Molekül, was zu einer 
schlechten Präsentation auf der Zelloberfläche führt, zurückzuführen sein. Darüber hinaus 
ZUSAMMENFASSUNG   
 54 
wird bei der Erkennung von MV-4;11 Zellen, die die FLT3-ITD-Mutation tragen, eine Rolle 
spielen, dass das FLT3986-Epitop sowohl vom Wildtyp als auch vom mutierten FLT3 
produziert wird. Während der In-vitro-Sicherheitstests entdeckten wir eine hohe, 
intrazelluläre FLT3-Expression in den Purkinje-Zellen des menschlichen Kleinhirns. Wir 
haben unseren Versuch, hochaffine FLT3-spezifische TCRs zu identifizieren, wegen 
möglicher zerebellärer Toxizität eingestellt. Wir glauben, dass FLT3 immer noch ein 
sicheres, wertvolles Ziel für andere Therapien als TCR-modifizierte T-Zellen sein könnte. 
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8. Abbreviations 
ACT Adoptive cell therapy 
AML Acute myeloid leukemia 
APC Antigen presenting cell 
2m beta-microglobulin 
CAR Chimeric antigen receptor 
CLP Common lymphoid progenitor 
CML Chronic myeloid leukemia 
CR  Complete remission 
DC  Dendritic cell 
DLBCL Diffused large B cell lymphoma 
DN  Double negative 
DP  Double positive 
FLT3 Fsm-like tyrosine kinase 3 
FLT3-ITD FLT3 internal tandem duplication 
FLT3L FLT3 ligand 
GL  Granular layer 
GvHD Graft-versus-host disease 
GvL Graft-versus-leukemia 
HLA Human leukocyte antigen 
HSC Hematopoietic stem cell 
HSCT Hematopoietic stem cell transplantation 
IF  Immunoflourescence 
IHC Immunohistochemistry 
iPSC induced pluripotent stem cells 
ITAM Immunoreceptor-based tyrosine activation motifs 
MCA Methylcholanthren 
MHC Major histocompatibility compex 
ML  Molecular layer 
MLL Mixed lineage leukemia 
MPP Multipotent progenitor 
PAMP Pathogen-associated molecular patterns 
PC  Purkinje cell 
pMHC peptide-MHC 
RACE Rapid amplification of cDNA ends 
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scFv Single chain variable fragment 
SPR Surface Plasmon resonance 
TAA Tumor-associated antigen 
TAP Transporter associated with antigen presentation 
TCR T cell receptor 
TIL  Tumor infiltrating lymphocyte 
TSA Tumor-specific antigen 
WT1 Willm’s tumor 1 
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